

---

---

CURRICULUM VITAE

**LARISA HUMMA CAVALLARI**

March 2020

---

---

**PERSONAL DATA**

Office Address: Department of Pharmacotherapy and Translational Research  
University of Florida, College of Pharmacy  
PO Box 100486  
1600 SW Archer Rd, Rm PG22  
Gainesville, FL 32610-0486

E-mail: lcavallari@cop.ufl.edu

Telephone: Office - (352) 273-8245  
Fax - (352) 273-6485

**EDUCATION**

1986-1989 Pre-pharmacy  
Georgia Southern University, Statesboro, Georgia

1989-1991 Bachelor of Science in Pharmacy, *Summa Cum Laude*  
University of Georgia, Athens, Georgia

1995-1997 Doctor of Pharmacy  
University of Georgia, Augusta, Georgia

**POST-DOCTORAL TRAINING**

1997-1998 *Pharmacy Practice Residency*  
Veterans Affairs Medical Center, Memphis, Tennessee

1998-2000 *Cardiovascular Pharmacogenomics Research Fellowship*  
University of Florida, Gainesville, Florida

**LICENSURE AND BOARD CERTIFICATION**

Licensure: Georgia License No. 16872 (Issued 1991)  
Illinois License No. 051-288656 (Issued 2001)

Board Certification: Board Certified Pharmacotherapy Specialist  
No. 299166, Effective December 31, 1999

## PROFESSIONAL APPOINTMENTS

07/1997 – 06/1998	Clinical Instructor, College of Pharmacy, University of Tennessee Memphis, Tennessee
07/1998 – 12/2000	Instructor / Recitation Leader, College of Pharmacy, University of Florida, Gainesville, Florida
01/2001 – 07/2009	Assistant Professor, Department of Pharmacy Practice University of Illinois at Chicago, Chicago, Illinois
01/2001 – present	Member of the Graduate Faculty, College of Pharmacy University of Illinois at Chicago, Chicago, Illinois
08/2006 – 03/2014	Co-Director, Pharmacogenomics Laboratory College of Pharmacy, University of Illinois at Chicago
08/2009 – 03/2014	Associate Professor (with Tenure), Department of Pharmacy Practice, University of Illinois at Chicago
08/2010 – 03/2014	Adjunct Associate Professor, Department of Biopharmaceutical Sciences, University of Illinois at Chicago
04/2011 – 03/2014	Faculty, Institute of Human Genetics, University of Illinois at Chicago
08/2012 – 03/2014	Faculty, Honors College, University of Illinois at Chicago
10/2013 – 03/2014	Faculty, Center for Pharmacoepidemiology & Pharmacoeconomic Research, University of Illinois at Chicago
04/2014 – present	Associate Professor (with Tenure), Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida
04/2014 – present	Director, Center for Pharmacogenomics and Precision Medicine, University of Florida
08/2014 – present	Graduate Faculty, Department of Pharmacotherapy and Translational Research, UF Graduate School, University of Florida
12/2014 – present	Member, Genetics Institute, University of Florida
02/2015 – 06/2017	Associate Chair, Department of Pharmacotherapy and Translational Research, University of Florida
10/2015 – present	Member, Cancer Center, University of Florida
03/2017 – present	Graduate Faculty, Department of Genetics and Genomics, UF Graduate School, University of Florida

07/2017 – present                      Head, Division of Translational Research, Department of  
Pharmacotherapy and Translational Research, University of  
Florida

## **PROFESSIONAL EXPERIENCE**

08/1991 – 12/1992                      Community Pharmacist, Phar-Mor Pharmacy, Stone Mountain, GA  
01/1993 – 07/1994                      Community Pharmacist, Eckerd Drugs, Lithonia, GA  
07/1994 – 08/1995                      Community Pharmacist, Eckerd Drugs, Savannah, GA  
09/1995 – 06/1997                      Staff Pharmacist, Eckerd Drugs, Augusta, GA  
07/1997 – 06/1998                      Clinical Pharmacist, VA Medical Center, Memphis, TN  
07/1998 – 12/2000                      Clinical Pharmacist, Heart Failure Clinic, Shands Hospital at the  
University of Florida, Gainesville, FL  
  
07/2000 – 12/2000                      Staff Pharmacist, VA Medical Center, Gainesville, FL  
03/2001 – 03/2003                      Clinical Pharmacist, Cardiology / Critical Care Unit  
University of Illinois Hospital & Health Sciences System, Chicago,  
IL  
  
01/2004 – 08/2012                      Clinical Pharmacist, Antithrombosis Clinic, University of Illinois  
Hospital & Health Sciences System, Chicago, IL  
08/2012 – 03/2014                      Co-Director, Warfarin Genetics Service, University of Illinois  
Hospital & Health Sciences System, Chicago, IL  
05/2014 – 09/2019                      Associate Director, University of Florida Precision Medicine  
Program  
10/2019 – present                      Director, University of Florida Precision Medicine Program

## **CLINICAL SERVICE DEVELOPMENT**

Co-Director, Warfarin Genetics Service, 2/2012 to 4/2014. The Warfarin Genetic Service is a clinical service supported by the University of Illinois Hospital & Health Sciences System Office of the Vice President for Health Affairs and designed to (1) provide a coordinated approach to integrating genotype-guided warfarin dose selection into INR-based, warfarin dose-adjustment approaches, and (2) provide consultative services and serve as an information resource on pharmacogenetics for warfarin. Approved by the Anticoagulation Task Force 2/13/2012; Approved by the Pharmacy and Therapeutics Committee 2/14/2012.

## **PROFESSIONAL AFFILIATIONS**

American Association of Colleges of Pharmacy, 2001 to 2008  
American College of Clinical Pharmacy, 1997 to present  
American Heart Association, 2003 to 2008, 2011 to present  
American College of Cardiology, 2012 to present  
American Society of Clinical Pharmacology and Therapeutics, 2004 to present  
Heart Failure Society of America, 1999 to 2012  
Rho Chi Pharmacy Honor Society, 1990 to present  
Pharmacogenetic Research Network, Affiliate member, 2009 to present  
International Warfarin Pharmacogenetics Consortium (IWPC), 2008 to present

## **RESEARCH GRANTS**

Current

Source: NIH, National Human Genome Research Institute; U01 HG007269 (competitive renewal)

Title: Sparking Advancements in Genomic Medicine

Time Period: July 2018 to June 2023

Amount: \$1,272,009 (direct), \$1,825,333 (total)

(Base funding – additional funding for clinical trial execution forthcoming)

Role: Co-Investigator, 0.9 calendar months (PI, Julie Johnson)

Source: NIH/NHGRI (T32 HG008958)

Title: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

Time Period: January 2018 through December 2022

Role: Executive Committee Member, 0 calendar months (MPIs, JA Johnson, TA Pearson)

Source: NIH/NCATS (UL1TR001427)

Title: “Together: Transforming and Translating Discovery to Improve Health”

Time Period: July 01, 2015 through June 30, 2020

Amount: \$2,156,476

Role: Co-Investigator, 1.8 calendar months (PI, David Nelson)

Source: NIH/NHGRI (3U01HG007269-06S2)

Title: Sparking Advancements in Genomic Medicine-GUARDD/ADOPT Supplement

Period: September 2019 to June 2023

Amount: \$1,679,834

Role: Co-Investigator, Site PI, 1.8 cal mos (PI, Julie Johnson)

Source: NIH/NHGRI (3U01HG007269-06S1)

Title: Sparking Advancements in Genomic Medicine-PGx Supplement

Period: September 2019 to June 2020

Amount: \$50,492

Role: Co-Investigator, Leader PGx Working Group, 1.2 cal mos (PI, Julie Johnson)

### Completed

Source: American College of Clinical Pharmacy Research Institute

Title: Merck and Company Cardiovascular Fellowship

Time Period: Accepted, then declined when AFPE fellowship (below) awarded.

Amount: \$22,500 (Total)

Role: Fellow (Preceptor, Julie Johnson)

Source: American Foundation for Pharmaceutical Education

Title: AFPE Clinical Pharmacy Post-Pharm.D. Fellowship in the Biomedical Research Sciences

Time Period: July 01, 1999 through June 30, 2001

Amount: \$55,000 (Total)

Role: Fellow (Preceptor, Julie Johnson)

Source: University of Illinois at Chicago Campus Research Board

Title: “Genetic Polymorphisms and Post-Infarction Remodeling”

Time Period: July 01, 2001 through June 30, 2002

Amount: \$12,100 (Total)  
Role: PI (20% effort)

Source: American Foundation for Pharmaceutical Education  
Title: 2002 AFPE Gateway Research Scholarship – Awardee: Elizabeth Zhong, Pharm.D. student  
Time Period: June 01, 2002 through May 31, 2003  
Amount: \$5,000 (Total)  
Role: Preceptor (Mentor)

Source: University of Illinois at Chicago Campus Research Board  
Title: “Cytochrome P450 2C9 Genotype and Phenotype in Cancer”  
Time Period: June 01, 2003 through May 31, 2004  
Amount: \$12,860 (Total)  
Role: Co-Investigator (PI, Stacy Shord)

Source: American Heart Association, Midwest Affiliate Scientist Development Grant  
Title: “Angiotensinogen Genotype and Spironolactone Response”  
Time Period: July 1, 2003 through June 30, 2006  
Amount: \$247,000 (Total)  
Role: PI (30% effort)

Source: American Foundation for Pharmaceutical Education; 2003-2004 American Association of Colleges of Pharmacy New Investigators Program  
Title: “Influence of Vitamin K Reductase Genotype on Warfarin Dose Requirements”  
Time Period: December 1, 2003 through December 1, 2004  
Amount: \$10,000 (Total)  
Role: PI (10% effort)

Source: American Health Assistance Foundation, National Heart Foundation  
Title: “Cyclooxygenase-1 Genotype and Aspirin Response in Stroke”  
Time Period: April 1, 2004 through March 31, 2006  
Amount: \$50,000 (Total)  
Role: PI (20% effort)

Source: American College of Clinical Pharmacy, Frontier Research Award  
Title: “Mineralocorticoid Receptor Genotype and Potassium Response to Spironolactone”  
Time Period: October 1, 2006 through September 30, 2007  
Amount: \$18,040 (Total)  
Role: PI (10% effort)

Source: University of Illinois at Chicago, Clinical and Translational Pilot Grant Program  
Title: “Effects of Cytochrome P450 2D6 Genotype on Pain Management with Codeine in Sickle Cell Disease”  
Time Period: January 1, 2007 through December 31, 2007  
Amount: \$49,685 (Total)  
Role: Co-Investigator (10% effort, PI, Stacy S. Shord)

Source: University of Illinois at Chicago, College of Pharmacy, Hans Vahlteich Research Award  
Title: “Genetic Determinants of Warfarin Dose Requirements in African Americans”

Time Period: October 2007 through September 2009  
Amount: \$45,000 (Total)  
Role: PI (20% effort)

Source: University of Illinois at Chicago, College of Pharmacy  
Title: Dean's 2008 PharmD Summer Research Fellowship - Awardee: Amarachi Otuwa, Pharm.D. student  
Time Period: May 2008 to August 2008  
Amount: \$6,000 (\$5,000 student stipend plus \$1000 research costs)  
Role: Preceptor (Mentor)

Source: Osmetech Molecular Diagnostics  
Title: "African American Sample Genotyping Study"  
Time Period: June 1, 2008 through May 31, 2009  
Amount: \$8,164 (Total)  
Role: PI

Source: NIH, National Institute on Aging R03 (AG033381-01)  
Title: "Genetic Determinants of Aldosterone Escape in Heart Failure"  
Time Period: September 30, 2008 through August 31, 2010  
Amount: \$128,740 (Total)  
Role: PI (5% effort)

Source: University of Illinois at Chicago, College of Pharmacy  
Title: David J. Riback 2009 Summer Research Fellowship - Awardee: Yana Blekhman, Pharm.D. student  
Project: "Genetic Determinants of Aldosterone Escape in Heart Failure"  
Time Period: Summer 2009  
Amount: \$6,000 (\$5,000 student stipend plus \$1000 research costs)  
Role: Preceptor (Mentor)

Source: University of Illinois at Chicago, College of Pharmacy  
Title: David J. Riback 2010 Summer Research Fellowship - Awardee: Katarzyna Drozda, Pharm.D. student  
Project: "Clinical and Functional Significance of the CYP2C9\*8 Allele"  
Time Period: May 2010 through August 2010  
Amount: \$6,000 (\$5,000 student stipend plus \$1000 research costs)  
Role: Preceptor (Mentor)

Source: American Heart Association, Midwest Affiliate Spring 2010 Clinical Research Program Award (10CRP3740026)  
Title: "Clinical Studies of Novel Genetic Variation Affecting Warfarin Dose in African Americans"  
Time Period: July 1, 2010 through June 30, 2011 (Returned with NIH R21 awarded)  
Amount: \$110,000  
Role: Co-Investigator (5% effort; PI, Minoli Perera)

Source: International Technidyne Corporation  
Title: "Evaluation of the ProTime InRhythm MicroCoagulation System by Inexperienced Self Tester"  
Time Period: July 1, 2010 through June 30, 2011

Role: Co-Investigator (2% effort; PI, Edith Nutescu)

Source: KL2RR029878 National Center for Research Resources & University of Illinois at Chicago Center for Clinical and Translational Science (CCTS)

Time Period: January 2010 through December 2012

Role: Mentor (PI, Edith Nutescu)

Source: University of Illinois at Chicago, College of Pharmacy

Title: David J. Riback 2011 Summer Research Fellowship - Awardee: Melissa McInnis, Pharm.D. student

Project: "Sodium Transporter Genes and Loop Diuretic Response in Heart Failure"

Time Period: May 2011 through August 2011

Amount: \$5,200 (\$4,200 student stipend plus \$1000 research costs)

Role: Preceptor (Mentor)

Source: University of Illinois at Chicago, College of Pharmacy

Title: David J. Riback 2011 Summer Research Fellowship - Awardee: Tara Berkson, Pharm.D. student

Project: "Pharmacodynamics of Novel Variation in the Vitamin K Epoxide Reductase (*VKORC1*) Gene"

Time Period: May 2011 through August 2011

Amount: \$5,200 (\$4,200 student stipend plus \$1000 research costs)

Role: Preceptor (Mentor)

Source: American Heart Association, Midwest Affiliate Spring 2010 Grant-In-Aid (10GRNT3750024)

Title: "Functional and Clinical Significance of the *CYP2C9\*8* allele"

Time Period: August 1, 2010 through July 31, 2012

Amount: \$142,000 (Total)

Role: PI (5% effort)

Source: University of Illinois at Chicago, College of Pharmacy

Title: David J. Riback 2012 Summer Research Fellowship - Awardee: Alexandra Goncharenko, Pharm.D. student

Project: "Epithelial Sodium Channel Genotype and Risk for Hyperkalemia with an Aldosterone Antagonist in Heart Failure"

Time Period: May 2012 to August 2012

Amount: \$4,750 (\$3,750 student stipend plus \$1000 research costs)

Role: Preceptor (Mentor)

Source: University of Illinois at Chicago Office of the Vice Chancellor for Research Areas of Excellence Program

Title: "Feasibility of an NIH Pharmacogenomics Research Network Grant Application"

Time Period January 15, 2012 through January 14, 2013

Amount: \$19,183 (Total)

Role: Co-PI (5% effort)

Source: American Society of Health-System Pharmacists Foundation Pharmacy Resident Practice-Based Research Grant (10-RES-608) – Awardee: Adam Bress, Pharm.D.

Project: "The Effect of Race and Genetic Variants on Diuretic Requirements in Patients with Systolic Heart Failure"

Time Period: January 1, 2011 through December 31, 2012  
Amount: \$5,000  
Role: Mentor (5% effort)

Source: NIH, NHLBI R21 (HL106097)  
Title: "Comprehensive Studies of Novel SNPs Affecting Warfarin Dose in African Americans"  
Time Period: July 1, 2011 through June 30, 2013 (no cost extension to June 30, 2014)  
Amount: \$79,239 (direct)  
Role: Co-Investigator (5% effort; PI, Minoli Perera, University of Chicago)

Source: University of Illinois at Chicago College of Pharmacy  
Title: David J. Riback 2013 Summer Research Fellowship - Awardee: Shan Wong, Pharm.D. student  
Project: "Effect of Novel Gene Variants on Warfarin Dose Prediction in African Americans"  
Time Period: May 2013 to August 2013  
Amount: \$6,000 (\$5,000 student stipend plus \$1000 research costs)  
Role: Preceptor (Mentor)

Source: University of Illinois at Chicago Office of the Vice Chancellor for Research Areas of Excellence Award  
Title: "Development of an NIH Pharmacogenomics Research Network Site Grant Application"  
Time Period: February 1, 2012 through July 31, 2014  
Amount: \$200,000  
Role: Co-PI (5% effort with Julio Duarte)

Source: University of Illinois Hospital & Health Sciences System (UI-Health) Office of the Vice President for Health Affairs  
Title: "Implementation of Warfarin Genetics at UI-Health"  
Time Period: August 15, 2012 through August 15, 2014  
Amount: \$220,000 (Total)  
Role: PI (40% effort, In-kind)

Source: University of Illinois at Chicago Office of the Vice Chancellor for Research Areas of Excellence Award  
Title: "Impact of Genetic Ancestry on Heart Failure Phenotype and Drug Response"  
Time Period: February 1, 2012 through January 31, 2014  
Amount: \$75,000 (Total)  
Role: PI (10% effort)

Source: University of Florida Clinical and Translational Science Institute Clinical Pilot Award  
Title: "Investigating the Impact of the *CYP2C19\*17* Allele on Voriconazole Exposure in Patients with Invasive Fungal Infections"  
Time Period: February 2015 through January 2016  
Amount: \$10,928 (Total)  
Role: Mentor (Awardee: Issam Hamadeh)

Source: Administrative Supplement to NIH/NHGRI (U01 HG 007269)  
Title: "Genomic Medicine Implementation: The PMP"



Time Period: June 16, 2014 through April 30, 2016  
Amount: \$194,056 (direct), \$242,218 (Total)  
Role: Co-Investigator, 0.6 calendar months (PI, Julie Johnson)

Source: Mallinckrodt Pharmaceuticals  
Title: 2015 Mallinckrodt Research Fellowship Award  
Time Period: September 1, 2015 through August 30, 2016  
Amount: \$160,000 (Total)  
Role: Mentor (Awardee: Scott Mosley)

Source: University of Florida Clinical and Translational Science Institute Clinical Pilot Award  
Title: "Integrating Pharmacogenomic Testing into a Child Psychiatry Clinic"  
Time Period: July 2016 through June 2017  
Role: Co-Investigator, 0.6 calendar months (In kind, PI, Carol Mathews)

Source: NIH/NHGRI (U01 HG 007269)  
Title: "Genomic Medicine Implementation: The Personalized Medicine Program (PMP)"  
Time Period: June 16, 2014 through May 30, 2017  
Amount: \$2,504,467 (Direct), \$3,749,997 (Total)  
Role: Co-Investigator, 3.0 calendar months (PI, Julie Johnson)

Source: FDA (U01-FD 005235)  
Title: "Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs"  
Time Period: September 1, 2014 through August 31, 2017  
Amount: \$1,555,246 (direct), \$2,332,870 (Total)  
Role: MPI, 3.6 calendar months (Larisa Cavallari, Julie Johnson)

Source: Administrative Supplement to NIH/NHGRI (U01 HG 007269)  
Title: "Genomic Medicine Implementation: The Personalized Medicine Education and Pharmacogenetics Administrative Supplement"  
Time Period: May 01, 2014 through April 30, 2018  
Amount: \$59,175  
Role: Co-Investigator, 1.2 calendar months (PI, Julie Johnson)

Source: Administrative Supplement to NIH/NHGRI (U01 HG 007269)  
Title: "Genomic Medicine Implementation: The Personalized Medicine PPI Administrative Supplement"  
Time Period: May 01, 2016 through April 30, 2018  
Amount: \$345,000 (Total)  
Role: Co-Investigator, 1.2 calendar months (PI, Julie Johnson)

Source: Canon Biomedical  
Title: "Development and Analytic Validation of a Customized Pharmacogenomics Panel"  
Time Period: June 1, 2016 through October 31, 2018  
Amount: \$392,614 (Direct), \$570,921 (Total)  
Role: PI, 0.24 calendar months

Source: University of Florida Clinical and Translational Science Institute  
Title: Genomic-Guided Pain management in Patients Undergoing Arthroplasty Surgery  
Time Period: May 25, 2018 through April 30, 2019 (NCE through October 31, 2019)

Amount: \$75,000 (Total)  
Role: PI, 0.12 calendar months (In kind)

Source: University of Florida Health Shands Hospital Quasi Endowment  
Title: Genotype-Guided Pain management in Patients Undergoing Arthroplasty Surgery  
Time Period: April 1, 2018 through October 25, 2019 (NCE through March 31, 2020)  
Amount: \$34,838 (Total)  
Role: PI, 0.12 calendar months (In kind)

Source: Administrative Supplement to FDA U01-FD005235  
Title: "Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs"  
Time Period: September 1, 2017 through August 31, 2018 (NCE through March 31, 2019)  
Amount: \$119,549 (Direct), \$182,312 (Total)  
Role: MPI, 3.6 calendar months (Larisa Cavallari, Julie Johnson)

Source: University of Florida Clinical and Translational Science Institute (5TL1TR001428-03)  
Title: "Investigation of the Association of Stress Hormones, Discrimination, and Nocturnal Blood Pressure dipping in the Jackson Heart Study"  
Time Period: August 16, 2017 through August 15, 2019  
Role: Mentor (Graduate Student, Leanne Dumeny)

## PATENT

Title: *CYP2C9\*8* allele correlates with decreased warfarin metabolism and increased warfarin sensitivity. U.S. Utility Patent Application No. 12/572,908. International Application No. PCT/US09/59413.  
Inventors: Coty W, **Cavallari L**.  
Filed: October 2, 2009; Published: May 27, 2010; Pub. No. US 2010/0130599.

## PUBLICATIONS

### Original Research

1. **(Cavallari) Humma LM**, Farmerie WG, Wallace MR, Johnson JA. Sequencing of  $\beta_2$ -adrenoceptor gene PCR products using Taq BigDye-Terminator chemistry results in inaccurate base-calling. *BioTechniques* 2000;29(5):962-964, 966, 968. PMID: 11084855.
2. Wang J, Mougey EB, David CJ, **(Cavallari) Humma LM**, Johnson JA, Lima JJ, Sylvester JE. Determination of human  $\beta_2$ -adrenoceptor haplotypes by denaturation selective amplification and subtractive genotyping. *Am J Pharmacogenomics* 2001;1(4):315-322. PMID: 12083963.
3. **(Cavallari) Humma LM**, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL, Wallace MR, Lewis JF, McNamara DM, Picoult-Newbert L, Pepine CJ, Johnson JA. Effects of  $\beta_1$ -adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. *Am J Cardiol* 2001;88(9):1034-1037. PMID: 11704005.
4. **(Cavallari) Humma LM**, Richardson HE, Lewis JF, McGorray, SP, Pepine CJ, Johnson JA. Dobutamine pharmacodynamics during dobutamine stress echocardiography and the

- impact of  $\beta$ -blocker withdrawal: A Report from the Women's Ischemic Syndrome Evaluation Study. *Pharmacotherapy* 2002;22(8):939-946. PMID: 12173796.
5. Andrisin TE, (**Cavallari**) Humma LM, Johnson JA. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. *Pharmacotherapy* 2002;22(8):954-960. PMID: 12173798.
  6. **Cavallari LH**, Fashingbauer LA, Beitelshes AL, Groo VL, Southworth MR, Viana MAG, Williams RE, Dunlap SH. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. *Pharmacotherapy* 2004;24(6):750-756. PMID 15222665.
  7. Aquilante CL, (**Cavallari**) Humma LM, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, Johnson JA. Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography. *Am J Cardiol* 2004;94(4):535-538. PMID: 15325950.
  8. Terra SG, McGorray SP, Wu R, McNamara DM, **Cavallari LH**, Walker JR, Wallace MR, Johnson BD, Bairey Merz CN, Sopko G, Pepine CJ, Johnson JA. Association between  $\beta$ -adrenergic receptor polymorphisms and their G-protein coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. *Int J Obes (Lond)* 2005;29(7):746-754. PMID: 15917856.
  9. **Cavallari LH**, Helgason CM, Brace LD, Viana MA, Nutescu EA. Sex differences in the antiplatelet effect of aspirin after stroke. *Ann Pharmacother* 2006;40(5):812-817. PMID: 16608908.
  10. **Cavallari LH**, Groo VL, Momary KM, Fontana D, Viana MAG, Vaitkus P. Racial difference in potassium response to spironolactone in heart failure. *Congest Heart Fail* 2006;12(4):200-205. PMID: 16894278.
  11. **Cavallari LH**, Momary KM, Groo VL, Viana MA, Camp JR, Stamos TD. Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. *Pharmacotherapy* 2007;27(6):801-812. PMID: 17542763.
  12. **Cavallari LH**, Groo VL, Momary KM, Stamos TD, Vaitkus PT. Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure. *Congest Heart Fail* 2007;13(5):275-279. PMID: 17917494.
  13. Momary KM, Shapiro NL, Viana MAG, Nutescu EA, Helgason CM, **Cavallari LH**. Factors influencing warfarin dose requirements in African Americans. *Pharmacogenomics* 2007;8(11):1535-1544. PMID: 18034618.
  14. Shord SS, **Cavallari LH**, Viana MAG, Momary K, Neceskas J, Molokie RE, Deyo K, Patel SR. Cytochrome P450 2C9 mediated metabolism in people with and without cancer. *Internat J Clin Pharmacol Ther* 2008;46(7):365-374. PMID: 18793590.
  15. Wang D, Chen H, Momary KM, **Cavallari LH**, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (*VKORC1*) affects gene expression and warfarin dose requirement. *Blood* 2008;112(4):1013-1021. PMID: 18523153. PMCID: PMC2515137

16. **Cavallari LH**, Fashingbauer LA, Camp JR, King ST, Geenen DL. Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. *J Renin Angiotensin Aldosterone Syst* 2008;9(3):146-153. PMID: 18957385.
17. Aquilante CL, Yarandi HN, **Cavallari LH**, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA. Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. *Pharmacogenomics J* 2008;8(6):408-415. PMID: 18253135.
18. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA on behalf of the International Warfarin Pharmacogenetics Consortium.\* Estimation of the warfarin dose with clinical and pharmacogenetic data. *New Engl J Med* 2009; 360(8):753-764. **\*\*Cavallari LH, author and data contributor.** PMID: 19228618. PMCID: PMC2722908
19. **Cavallari LH**, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA. Predictors of unstable anticoagulation in African Americans. *J Thromb Thrombolysis* 2009;27(4):430-437. PMID: 18563532.
20. Momary KM, Shapiro NL, Brace LD, Shord SS, Grossi E, Viana MA, Helgason CM, Nutescu EA, **Cavallari LH**. Influence of cyclooxygenase-1 genotype on *ex-vivo* aspirin response in patients at risk for stroke. *Cerebrovascular Dis* 2009;27(6):585-593. PMID: 19390185.
21. Shord SS, **Cavallari LH**, Gao W, Jeong HY, Deyo K, Patel SR, Camp JR, Labott SM, Molokie RE. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. *Eur J Clin Pharm* 2009;65(7):651-658. PMID: 19357842.
22. Nochowitz B, Shapiro NL, Nutescu EA, **Cavallari LH**. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. *Ann Pharmacother* 2009;43(7):1165-1172. PMID: 19549747.
23. **Cavallari LH**, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. *Pharmacotherapy* 2010;30(1):1-9. PMID: 20030467. **Included in the NIH based Genetic Association Database (<http://geneticassociationdb.nih.gov>; records 574145 and 593486).**
24. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, **Cavallari LH**, Ridker PM, Grice GR, Miller RD, Gage BF. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. *Clin Pharmacol Ther* 2010;87(4):445-451. PMID: 20200517. PMCID: PMC2928561
25. **Cavallari LH**, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA. Genetic and clinical predictors of warfarin dose requirements in African Americans. *Clin Pharmacol Ther* 2010;87(4):459-464. PMID: 20072124.
26. Limdi NA, Wadelius M, **Cavallari L**, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin

- Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single *VKORC1* polymorphism is predictive of dose across 3 racial groups. *Blood* 2010;115(18):3827-3834. PMID: 20203262. PMCID:PMC2865873.
27. Limdi NA, Limdi MA, **Cavallari L**, Anderson AM, Crowley MR, Baird MF, Allon M, Beasley TM, Warfarin dosing in patients with impaired kidney function. *Am J Kidney Dis* 2010;56(5):823-831. PMID: 20709439. PMCID:PMC2963672
28. Perera MA, Gamazon E, **Cavallari LH**, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ. The missing association: sequencing-based discovery of novel SNPs in *VKORC1* and *CYP2C9* that affect warfarin dose in African Americans. *Clin Pharmacol Ther* 2011;89(3):408-415. PMID: 21270790. PMCID:PMC3625373
29. **Cavallari LH**, Momary KM, Patel SR, Shapiro NL, Nutescu EA, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. *Blood Cells Mol Dis* 2011;46(2):147-150. PMID: 21185752.
30. Cochran KA, **Cavallari LH**, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. *Ther Drug Monit* 2011;33(4):433-438. PMID: 21743381. PMCID:PMC3212440
31. **Cavallari LH**, Butler C, Langae TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. *Pharmacotherapy* 2011;31(8):785-792. PMID: 21923605.
32. **Cavallari LH**, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. Association of the *GGCX* (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. *Pharmacogenet Genomics* 2012;22(2):152-158. PMID: 22158446. PMCID:PMC3261355. **Curators' favorite paper, Pharmacogenomics Knowledge Base (PharmGKB), December 2011.**
33. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, **Cavallari LH**. Decreased warfarin clearance associated with the *CYP2C9* R150H (\*8) polymorphism. *Clin Pharmacol Ther* 2012;91(4):660-665. PMID: 22378156. **\*\*Referenced in the Human Cytochrome P450 (CYP) Allele Nomenclature Database (www.cypalleles.ki.se).**
34. Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, **Cavallari LH**, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langae T, Siguret V, Lorient MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C. Impact of the *CYP4F2* p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. *Clin Pharmacol Ther* 2012;92(6):746-756. PMID: 23132553.
35. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, **Cavallari LH**. Effect of *NQO1* and *CYP4F2* genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. *Pharmacogenomics* 2012;13(16):1925-1935. PMID: 23215885. PMCID:PMC3586586.

36. **Cavallari LH**, Vaynshteyn D, Freeman KM, Wang D, Perera MA, Takahashi H, Drozda K, Patel SR, Jeong H. *CYP2C9* promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in *CYP2C9*\*8-mediated effects. *Pharmacogenet Genomics* 2013 Apr;23(4):228-231. PMID: 23376925. PMCID:PMC3629689.
37. Shahin MH, **Cavallari LH**, Perera MA, Khalifa SI, Misher A, Langae T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA. *VKORC1* Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Thromb Haemost* 2013 Jun;109(6):1045-1050. PMID: 23571513. PMCID:PMC3712827.
38. Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah, E, Stamos TD, Wing C, Garcia JGN, Kittles R, **Cavallari LH**. Association of aldosterone synthase polymorphism (*CYP11B2* -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. *PLoS One* 2013 Jul 30;8(7):e71268, 1-10. PMCID:PMC3728110.
39. Perera MA,\* **Cavallari LH**,\* Limdi NA,\* Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langae TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet* 2013 Aug; 382 (9894): 790-796. PMID: 23755828. PMCID:PMC3759580  
**\*Contributed equally to the writing of this paper.**
40. Vardeny O, **Cavallari LH**, Claggett B, Desai AS, Anand I, Rossignol P, Zannad, F, Pitt B, Solomon SD. Race influences the safety and efficacy of spironolactone in severe heart failure. *Circ Heart Fail* 2013 Sept;6(5):970-976. PMID 23940307.
41. Drozda K, Labinov Y, Jiang, R, Thomas MR, Wong SS, Patel SR, Nutescu EA, **Cavallari LH**. A pharmacogenetics service experience for pharmacy students, residents, and fellows. *Am J Pharm Ed* 2013 Oct;77(8):175. PMID 24159216. PMCID:PMC3806959.
42. Daneshjou R, Tatonetti NP, Karczewski KJ, Sagreiya H, Bourgeois S, Drozda K, Burmester JK, Tsunoda T, Nakamura Y, Kubo M, Tector M, Limdi NA, **Cavallari LH**, Perera M, Johnson JA, Klein TE, Altman RB. Pathway analysis of genome-wide data improves warfarin dose prediction. *BMC Genomics* 2013;14 Suppl 3:S11. PMID: 23819817. PMCID:PMC3829086.
43. Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JGN, **Cavallari LH**. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. *Pharmacotherapy* 2013 Nov;33(11): 1156-1164. PMID: 23864527. PMCID:PMC3985126.
44. Patel HN, Urgan ID, Zueger PM, **Cavallari LH**, Pickard AS. Stakeholder views on pharmacogenomic testing. *Pharmacotherapy* 2014 Feb;34(2):151-165. PMID: 24167008.

45. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AH, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, **Cavallari LH**, Perera MA. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. *Pharmacogenomics J* 2014 Jun; 14(3):223-228. PMID: 24018621. PMCID: PMC4016191
46. Daneshjou R, Gamazon ER, Burkley B, **Cavallari LH**, Johnson JA, Klein TE, Limdi N, Hillenmyer S, Percha B, Karczewski KJ, Langaee T, Patel SR, Bustamante CD, Altman RB, Perera MA. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. *Blood* 2014 Oct 2;124(14):2298-2305. PMID: 25079360. PMCID: PMC4183989. **Curators' Paper of Interest, Pharmacogenomics Knowledge Base (PharmGKB), August 2014.**
47. Patel SR, Langaee TY, Wong SS, **Cavallari LH**. Pyrosequencing of the *CYP2C9* -1766T>C polymorphism as a means of detecting the *CYP2C9*\*8 allele. *Pharmacogenomics* 2014 Sep; 15(13):1717-1722. PMID 25410896.
48. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, **Cavallari LH**. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. *Pharmacogenet Genomics* 2015 Feb;25(2):73-81. PMID 25461246. PMCID: PMC4280295. **Curators' Paper of Interest, Pharmacogenomics Knowledge Base (PharmGKB), December 2014.**
49. Nagai R, Ohara M, **Cavallari LH**, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H. Factors influencing pharmacokinetics of warfarin in African Americans: implications for pharmacogenetic dosing algorithms. *Pharmacogenomics* 2015 Mar;16(3):217-225. PMID: 25712185.
50. Hernandez W, Aquino-Michaels K, Drozda K, Patel S, Jeong Y, Takahashi H, **Cavallari LH**, Perera MA. Novel single nucleotide polymorphism in *CYP2C9* is associated with changes in warfarin clearance and *CYP2C9* expression levels in African Americans. *Transl Res* 2015 Jun;165(6):651-657. PMID: 25499099. PMCID: PMC4433569.
51. Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, **Cavallari LH**, Burmester JK, Rettie AE, Klein TE, Johnson JA, Hutz MA, Suarez-Kurtz G. Genome-wide association study of warfarin maintenance dose in a Brazilian sample. *Pharmacogenomics* 2015 July;16(11):1253-1263. PMID 26265036. PMCID: PMC4573240.
52. Weitzel KW, Alexander M, Bernhardt BA, Calman N, Carey DJ, **Cavallari LH**, Field JR, Hauser D, Junkins HA, Levin PA, Levy K, Madden EB, Manolio TA, Ogdiss J, Orlando LA, Pyeritz R, Wu RR, Shuldiner AR, Bottinger EP, Denny JC, Dexter PR, Flockhart DA, Horowitz CR, Johnson JA, Kimmel SE, Levy MA, Pollin TI, Ginsburg GS for the IGNITE Network. The IGNITE network: a model for genomic medicine implementation and research. *BMC Med Genomics* 2016 Jan;9(1):1. PMCID: PMC4700677.
53. Hamadeh IS, Shahin MH, Lima SM, Oliveira F, Wilson L, Khalifa SI, Langaee TY, Cooper-DeHoff R, **Cavallari LH**, Johnson JA. Impact of *GGCX*, *STX1B*, and *FPGS* polymorphisms on warfarin dose requirements in European-Americans and Egyptians. *Clin Transl Sci* 2016 Feb;9(1):36-42. PMID: 26751406. PMCID:PMC4760888.

54. Hernandez W, Gamazon ER, Smithberger E, O'Brien TJ, Harralson AF, Tuck M, Barbour A, Kittles RA, **Cavallari LH**, Perera MA. Novel genetic predictors of venous thromboembolism risk in African Americans. *Blood* 2016 Apr;127(15):1923-9. PMID: PMC4832509.
55. Daneshjou R, **Cavallari LH**, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson JA, Klein TE, Bustamante CD, Roden DM, Shaffer C, Denny JC, Zehnder JL, Altman RB. Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. *Mol Genet Genomic Med* 2016 Jun;4(5):513-520. PMID: PMC5023936.
56. Kubo K, Ohara M, Tachikawa M, **Cavallari LH**, Lee MT, Wen MS, Scordo MG, Nutescu EA, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Takahashi H. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. *Pharmacogenomics J* 2017 Dec;17(6): 494-500. PMID: 27503578.
57. Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, **Cavallari LH**. Circulating procollagen type III N-terminal peptide and mortality risk in African Americans with heart failure. *J Card Fail* 2016 Sep;22(9):692-699. PMID: 26721774. PMID: PMC4917490.
58. Weitzel KW, McDonough CW, Eley AR, Burkley B, **Cavallari LH**, Johnson JA. Effects of using personal genotype data on student learning and attitudes in a pharmacogenomics course. *Am J Pharm Educ* 2016 Sep;80(7):122. PMID: PMC5066925.
59. Takahashi H, Ohara M, Shibata S, Lee MT, **Cavallari LH**, Nutescu EA, Scordo MG, Pengo V, Padrini R, Atsuda K, Matsubara H, Chen YT, Echizen H. Correlations between the enantio- and regio-selective metabolisms of warfarin. *Pharmacogenomics* 2017 Jan;18(2):133-142. PMID: 27995809.
60. Langaee T, Stauffer L, Galloway C, Solayman M, **Cavallari L**. Cross-validation of high-resolution melting analysis-based genotyping platform. *Genet Test Mol Biomarkers* 2017 Apr;21(4):259-264. PMID: 28384046.
61. Kansal MM, Mansour IN, Ismail S, Bress A, Wu G, Mirza O, Marpadga R, Gheith H, Kim Y, Li Y, **Cavallari L**, Stamos T. Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients. *Clin Cardiol* 2017 May;40(5):314-321. PMID: 28272832.
62. Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, O'Brien TJ, Harralson AF, Tuck M, Barbour A, **Cavallari LH**, Perera MA. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. *J Thromb Haemost* 2017 Apr;15(4):735-743. PMID: 28135054.
63. **Cavallari LH**, Weitzel KW, Eley AR, Liu X, Mosley SA, Smith DM, Staley BJ, Winterstein AG, Mathews, CA, Franchi F, Rollini F, Angiolillo DJ, Starostik P, Clare-Salzler MJ, Nelson DR, Johnson JA. Institutional profile: University of Florida Health Personalized Medicine Program. *Pharmacogenomics* 2017 Apr;18(5):421-426. PMID: PMC5558508.
64. Arwood MJ, Deng J, Drozda K, Pugach O, Nutescu EA, Schmidt S, Duarte JD, **Cavallari LH**. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic



- dosing in a real-world setting: a proposal for a new pharmacogenetic dosing approach. *Clin Pharmacol Ther* 2017 May;101(5):675-683. PMID: PMC5395307.
65. Hamadeh IS, Klinker KP, Borgert SJ, Richards AI, Li W, Mangal N, Hiemenz JW, Schmidt S, Langaee TY, Peloquin CA, Johnson JA, **Cavallari LH**. Impact of the *CYP2C19* genotype on voriconazole exposure in adults with invasive fungal infections. *Pharmacogenet Genomics* 2017 May;27(5):190-196. PMID: PMC5391994.
66. Luzum JA, Pakyz RE, Eelsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, **Cavallari LH**, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR for the Pharmacogenomics Research Network Translational Pharmacogenetics Program. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetics implementation across diverse healthcare systems. *Clin Pharmacol Ther* 2017 Sep;102(3):502-510. PMID: 28090649. PMID: PMC5511786.
67. Chong HY, Mohamed Z, Tan LL, Wu DBC, Shabaruddin FH, Dahlui M, Apal Sammy YD, Snyder SR, Williams MS, Hao J, **Cavallari LH**, Chaiyakunapruk N. Is universal *HLA-B\*15:02* screening a cost-effective option in an ethnically-diverse population? A case study of Malaysia. *Br J Dermatol* 2017 Oct;177(4):1102-1112. PMID: PMC5617756.
68. Sperber NR, Carpenter JS, **Cavallari LH**, J. Damschroder L, Cooper-DeHoff RM, Denny JC, Ginsburg GS, Guan Y, Horowitz CR, Levy KD, Levy MA, Madden EB, Matheny ME, Pollin TI, Pratt VM, Rosenman M, Voils CI, Weitzel KW, Wilke RA, Wu RR, Orlando LA. Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. *BMC Med Genomics* 2017 May; 10(1):35. PMID: PMC55441047.
69. Lima SM, Pitsis AA, Kelpis TG, Shahin MH, Langaee TY, **Cavallari LH**, Theofilogiannakos EK, Boudoulas H, Boudoulas KD. Matrix metalloproteinase polymorphisms in patients with floppy mitral valve/mitral valve prolapse (FMV/MVP) and FMV/MVP syndrome. *Cardiology* 2017;138(3):179-185. PMID: 28750369.
70. Yuliwulandari R, Kristin E, Prayuni K, Sachrowardi Q, Suyatna FD, Menaldi, SL, Wichukchinda N, Mahasirimongkol S, **Cavallari LH**. Association of the *HLA-B* alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the *HLA-B\*75* serotype. *Pharmacogenomics* 2017 Dec; 18(8):1643-1648. PMID 29053440. PMID: PMC5753619.
71. **Cavallari LH**, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardatti AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Eelsey AR, Hamadeh IS, Harada S, Hillegeass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA on behalf of the IGNITE

- Network. Multi-site investigation of outcomes with implementation of *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *JACC Cardiovasc Interv* 2018 Jan 22; 11(2):181-191. PMID: 29102571. PMCID: PMC5775044.
72. Lee YM, Manzoor BS, **Cavallari LH**, Nutescu EA. Facilitators and barriers to the adoption of pharmacogenetic testing in an inner city population. *Pharmacotherapy* 2018 Feb;38(2):205-216. PMID: 29286540.
73. Weitzel KW, Smith DM, Elsey AR, Duong BQ, Burkley B, Clare-Salzler M, Gong Y, Higgins TA, Kong B, Langae T, McDonough CW, Staley BJ, Vo TT, Wake DT, **Cavallari LH**, Johnson JA. Implementation of standardized clinical processes for *TPMP* testing in a diverse multidisciplinary population: challenges and lessons learned. *Clin Trans Sci* 2018 Mar;11(2):175-181. PMID: 29351371. PMCID:PMC5867028.
74. Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langae T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod H, **Cavallari LH**. Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. *Contemp Clin Trials* 2018 Mar 10;68:7-13. PMID: 29535047. PMCID: PMC5899651.
75. **Cavallari LH**, Franchi F, Rollini F, Been L, Rivas A, Agarwal M, Smith DM, Newsom K, Gong Y, Elsey AR, Starostik P, Johnson JA, Angiolillo DJ. Clinical implementation of rapid *CYP2C19* genotyping to guide antiplatelet therapy after percutaneous coronary intervention. *J Transl Med* 2018 Apr 11;16(1):92. PMID: 29642909. PMCID: PMC5896099.
76. Duarte JD, Kansal M, Desai AA, Riden K, Arwood MJ, Yakob AA, Stamos TD, **Cavallari LH**, Zamanian RT, Shah SJ, Machado RF. Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. *Pulm Circ* 2018 Apr-Jun;8(2):2045894018773049. PMID: 29718770. PMCID: PMC5946646.
77. Fathy S, Shahin MH, Langae T, Khalil BM, Saleh A, Sabry NA, Schaalman MF, El Wakeel LL, **Cavallari LH**. Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. *Pharmacogenet Genomics* 2018 Sep;28(9):207-213. PMID: 30188374.
78. Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, **Cavallari LH**, Lee CR; for the NHGRI Implementing GeNomics In PracTicE (IGNITE) Network. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther*. 2018 Oct; 104(4): 664-674. PMID: [29280137](#). PMCID: [PMC6019555](#). DOI: [10.1002/cpt.1006](#).
79. Mangal N, Hamadeh IS, Arwood MJ, Cavallari LH, Samant TS, Klinker KP, Bulitta J, Schmidt S. Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults. *Clin Pharmacol Ther* 2018 Nov;104(5):957-965. PMID: 29351371. PMCID: 6037619.
80. De T, Alarcon C, Hernandez W, Liko I, **Cavallari LH**, Duarte JD, Perera MA. Association of genetic variants with warfarin-associated bleeding among patients of African Descent. *JAMA* 2018 Oct;120(16):1670-1677. PMID: 30357299. PMCID: PMC6233811.

81. Danese E, Raimondi S, Montagnana M, Tagetti A, Langae T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Botton MR, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, **Cavallari LH**, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kringen MK, Bente Foss Haug K, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Lorient MA, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava C. The effect of *CYP4F2*, *VKORC1*, and *CYP2C9* in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals. *Clin Pharmacol Ther* 2019 Jun; 105(6):1477-1491. PMID 30506689. PMCID: PMC6542461.
82. Smith DM, Weitzel KW, Elsey AR, Langae T, Gong Y, Wake DT, Duong BQ, Hagan M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, **Cavallari LH**. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. *Genet Med* 2019 Aug;21(8):1842-1850. PMID 30670877. PMCID: PMC6650382.
83. Langae T, El Roubi N, Stauffer L, Galloway C, **Cavallari LH**. Development and cross-validation of high-resolution melting analysis-based cardiovascular pharmacogenetics genotyping panel. *Genet Test Mol Biomarkers* 2019 Mar;23(3):209-214. PMID: 30758238.
84. Ohara M, Suzuki Y, Shinohara S, Gong IY, Schmerk CL, Tirona RG, Schwarz UI, Wen MS, Lee MTM, Mihara K, Nutescu EA, Perera MA, **Cavallari LH**, Kim RB, Takahashi T. Differences in warfarin pharmacodynamics and predictors of response among three racial populations. *Clin Pharmacokinet* 2019 Aug;58(8):1077-1089. PMID 30815847.
85. **Cavallari LH**, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshes AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC; on behalf of the IGNITE Network. Multi-site investigation of strategies for the clinical implementation of *CYP2D6* genotyping to guide drug prescribing. *Genet Med* 2019 Oct;21(10):2255-2263. PMID:30894703. PMCID: PMC6754805
86. Cicali EJ, Weitzel KW, Elsey AR, Orlando FA, Vinson M, Mosley S, Smith DM, Davis R, Drum L, Estores D, Franciosi JP, Hagen MG, Jerkins GJ, Mercado ES, Nainaparampil J, Padron A, Rosenberg EI, Wright A, Schmidt SO, Mathews, CA, **Cavallari LH**,\* Johnson JA.\* Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. *Genet Med* 2019 Oct;21(10):2264-2274. PMID: 30926959. PMCID: PMC6768772. \*Contributed equally.
87. Snyder SR, Hao J, **Cavallari LH**, Geng Z, Elsey A, Johnson JA, Mohamed Z, Chaiyakunapruk N, Chong HY, Dahlui M, Shabaruddin FH, Patrinos GP, Mitropoulou C, Williams MS. Generic cost effectiveness models: a proof of concept of a tool for informed

- decision-making for public health precision medicine. *Public Health Genomics*. 2019;21(5-6):217-227. PMID: 31189173. PMCID: PMC6762029.
88. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Rossi JS, Clarke M, Cicci JD, **Cavallari LH**, Weck KE, Stouffer GA, Lee CR. Frequency and clinical outcomes of *CYP2C19* genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. *Genet Med* 2020 Jan;22(1):160-169. PMID:31316169. PMCID: PMC6946839. **\*Highlighted by NIH/NHGRI as one of top 10 advances in genomic medicine in 2019 (doi.org/10.1016/j.ajhg.2019.11.006.)**
89. Kim K, Touchette DR, **Cavallari LH**, Ardati AK, DiDomenico RJ. Cost-effectiveness of strategies to personalize the selection of P2Y<sub>12</sub> inhibitors in patients with acute coronary syndrome. *Cardiovasc Drugs Ther* 2019 Oct;33(5):533-564. PMID:31367811.
90. Sarhan NM, Shahin MH, El Roubay NM, El-Wakeel, LM, Solayman MH, Langaee T, Khorshid H, Schaalan MF, Sabri NA, **Cavallari LH**. Effect of genetic and non-genetic factors on the clinical response to mineralocorticoid receptor antagonists therapy in Egyptians with heart failure. *Clin Transl Sci* 2019 Sep 27. doi: 10.1111/cts.12702. [Epub ahead of print] PMID:31560448. PMCID: PMC6951455.
91. Bader L, Mahfouz A, Kasem M, Mohammed S, Alsaadi S, Abdelsamad O, Elenani R, Soaly E, Elzouki A, Rizk N, Khalifa S, Shahin M, **Cavallari LH**, Mraiche F, Elewa H. The effect of genetic and non-genetic factors on warfarin dose variability in Qatari population. *Pharmacogenomics J* 2019 Oct 25. doi: 10.1038/s41397-019-0116-y. [Epub ahead of print]. PMID:31653973.
92. Lteif C, Arwood MJ, Kansal M, **Cavallari LH**, Desai AA, Duarte JD. Beta-blocker dose stratifies mortality risk in a racially diverse heart failure population. *J Cardiovasc Pharmacol* Mar 2020;75(3):250-258. PMID: 31895871.
93. El Roubay N, Alrwisan A, Langaee T, Lipori G, Angiolillo DJ, Franchi F, Riva A, Elsey A, Johnson JA, **Cavallari LH**,\* Winterstein AG.\* Clinical utility of pharmacogene panel-based testing in patients undergoing percutaneous coronary intervention (PCI). *Clin Transl Sci* 2019 Nov 23. doi: 10.1111/cts.12729. [Epub ahead of print]. PMID: 31758664. \*Contributed equally.
94. Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, **Cavallari LH**, Marcatto LR, Beasley MT, Perera MA, Limdi NA, Santos PC, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Genetic factors influencing warfarin dose in Black-African patients: a systematic review and meta-analysis. *Clin Pharmacol Ther* 2019 Dec 23. doi: 10.1002/cpt.1755. [Epub ahead of print]. PMID: 31869433.
95. Cicali EJ, Smith DM, Duong BQ, Kovar LG, **Cavallari LH**, Johnson JA. A scoping review of the evidence behind CYP2D6 inhibitor classifications. *Clin Pharmacol Ther* 2020 Jan 7. doi: 10.1002/cpt.1768 [Epub ahead of print]. PMID: 31910286.
96. Limdi NA, **Cavallari LC**, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF on behalf of Implementing GeNomics In pracTice (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx). Cost-effectiveness of CYP2C19-guided

antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. *Pharmacogenomics J* 2020 Feb 11. doi: 10.1038/s41397-020-0162-5. [Epub ahead of print].

97. El Rouby N, Marcatto LR, Claudio K, Tavares LC, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, de Lima Santos, PC, Duconge J, **Cavallari LH**. Multi-site investigation of genetic determinants of warfarin dose variability in Latinos. [Submitted].
98. Duong BQ, Arwood MJ, Hicks JK, Beitelshes AL, Franchi F, Houder JT, Limdi NA, Melloy KJ, Obeng AO, Petry N, Tuteja S, Eley AR, **Cavallari LH**, Wiisanen K. Development of Customizable Implementation Guides to Support Clinical Adoption of Genomic Medicine: Experiences of the Implementing Genomics in Practice (IGNITE) Network. [Submitted].
99. Beitelshes AL, Stevenson JM, El Rouby N, Dillon C, Empey PE, Fielstein EM, Johnson JA, Limdi NA, Ong HH, Peterson JF, Rosenman MB, Skaar TC, Tuteja S, **Cavallari LH** on behalf of the IGNITE Pharmacogenetics Working Group. Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. [Submitted].
100. Ramsey LB, Ong HH, Tang LA, Schildcrout JS, Shi Y, Hicks JK, Blake KV, Williams H, Rosenman M, Teal E, Skaar TC, Beitelshes AL, Aquilante CL, Kao DP, Tuteja S, Empey PE, Horvat CM, Limdi NA, Davis B, Cimino J, Obeng AO, Ellis SB, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, **Cavallari LH**, El Rouby N, Lipori GP, Winterstein AG, Peterson J, Van Driest SL on behalf of the IGNITE Pharmacogenetics Working Group. Opportunity for pharmacogenetic prescribing in pediatric hospitals in the IGNITE Network. [In preparation].
101. Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey L, Shi Y, Tang LA, Aquilante CL, Beitelshes AL, Blake KV, Empey PE, Dao DP, Lemkin KL, Limdi NA, Lipori GP, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley L, Williams H, Winterstein AG, Van Driest S, **Cavallari LH**, Peterson JF on behalf of the IGNITE Pharmacogenetics Working Group. Prescribing rates of drugs influenced by pharmacogenetic variants among adult patients across 11 US Health Systems. [In preparation].

#### Reviews, Case Reports, and Commentaries

102. **(Cavallari) Humma LM**. Prevention and treatment of drug-resistant tuberculosis. (Review) *Am J Health-Syst Pharm* 1996;53(19):2291-2298; quiz 2335-2336. PMID: 8893067.
103. Solomon DK, Gorley DR, Brown JR, Gorley GA, **(Cavallari) Humma LM**. Technology assessment and the drug use process. (Review) *Am J Manag Care* 1999;5(2):220-229; quiz 230-232. PMID: 10346517.
104. **(Cavallari) Humma LM**, Swims MP. Bupropion mimics a transient ischemic attack. (Case Report) *Ann Pharmacother* 1999;33(3):305-307. PMID: 10200854.
105. **(Cavallari) Humma LM**. Predicting adverse drug reactions using pharmacogenetics. (Invited Review) *Clin Trend Pharm Practice*. 2001;15(8):104-123.

106. Johnson JA, **(Cavallari) Humma LM**. Pharmacogenetics of cardiovascular drugs. (Invited Review) *Brief Funct Genomic Proteomic* 2002;1(1): 66-79. PMID: 15251067.
107. **(Cavallari) Humma LM**, Terra, SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. (Invited Review) *Am J Health Syst Pharm* 2002;59(13):1241-1252. **\*\*Included in the NIH Genetic Association Database (<http://geneticassociationdb.nih.gov>), Record 123152.** PMID: 12116890.
108. **(Cavallari) Humma LM**. Predicting drug response with pharmacogenomics. (Invited Review) *Applied Genomic Proteomic* 2002;1(3):151-168.
109. Southworth MR, **Cavallari LH**. New treatment option for heart failure patients: Eplerenone. (Invited Review). *J Cardiovasc Nurs* 2004;19(6):390-395. PMID: 15529060.
110. Johnson JA, **Cavallari LH**. Cardiovascular Pharmacogenomics. (Invited Review) *Exp Physiol* 2005;90(3):283-289. **\*\*One of Top 10 Most-Frequently-Read Articles in Exp Physiol during July 2005.** PMID: 15778411.
111. **Cavallari LH**, Limdi NA. Warfarin pharmacogenomics. (Invited Review) *Curr Opin Mol Ther* 2009;11(3):243-251. PMID: 19479657.
112. **Cavallari LH**, Momary KM. Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease (Invited Review). *Curr Treat Options Cardiovasc Med* 2009;11(3):191-200. PMID: 19433014. **\*\*Curated for the NIEHS-funded Comparative Toxicogenomics Database (<http://ctdbase.org>) April 2012.**
113. Aquilante CL, Beitelshes AL, **Cavallari LH**, Lee CR, Maciejewski S, Momary K, Vardeny O, Zineh I. Significant articles in the field of cardiovascular pharmacogenomics. (Invited review) *Pharmacotherapy* 2009;29(9):1110-1151.
114. **Cavallari LH**, Overholser BR, Anderson D, Boyce E, Buie L, Formea CM, Gallagher JC, Hayney MS, Oestreich J. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. (Invited Commentary) *Pharmacotherapy* 2010;30(6):228e-235e.
115. Johnson JA, **Cavallari LH**, Beitelshes AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. (Invited Review). *Clin Pharmacol Ther* 2011;90(4):519-531. PMID: 21918509. PMCID: PMC3190669.
116. **Cavallari LH**, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. (Invited Review) *Pharmacogenomics Pers Med* 2011;4:123-136. PMID: 23226058. PMCID: PMC3513224.
117. **Cavallari LH**, Shin J, Perera MA. The role of pharmacogenomics in the management of traditional and novel oral anticoagulants. (Invited Review) *Pharmacotherapy* 2011;31(12):1192-1207. PMID: 22122181. PMCID: PMC3655546.
118. **Cavallari LH**, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. (Invited Review) *Future Cardiol* 2012;8(4):563-576. PMID: 22871196. PMCID: PMC3463230

119. **Cavallari LH.** Tailoring drug therapy based on genotype. (Invited Review) *J Pharm Practice* 2012;25(4):413-416. PMID: 22907842.
120. Johnson JA, **Cavallari LH.** Pharmacogenetics and cardiovascular disease – implications for personalized medicine. (Invited Review) *Pharmacol Rev* 2013 Jul;65(3):987-1009. PMID: 23686351. PMCID: PMC3698938.
121. **Cavallari LH,** Nutescu EA, Duarte J. Personalized medicine in cardiology: the time for genotype-guided therapy is now. (Invited Commentary) *Future Cardiol* 2013;9(4):459-464. PMID: 23834684.
122. Perera MA, **Cavallari LH,** Johnson JA. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. (Invited macroscopy) *Clin Pharmacol Ther* 2014 Mar;95(3):242-244. PMID: 24548987. PMCID: PMC4131541.
123. Lee YM, Eggen J, Soni V, Drozda K, Nutescu EA, **Cavallari LH.** Warfarin dose requirements in a patient with the *CYP2C9\*14* allele. (Case Report) *Pharmacogenomics* 2014 May;15(7):909-914. PMID: 24956244. PMCID: PMC4151614.
124. **Cavallari LH,** Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. (Invited Commentary) *Clin Pharmacol Ther* 2014 Jul;96(1):22-24. PMID: 24942399.
125. Johnson JA, **Cavallari LH.** Warfarin Pharmacogenetics. (Invited Review) *Trends Cardiovasc Med* 2015 Jan;25(1):33-41. PMID 25282448. PMCID: PMC4278947. **Curators' paper of interest, Pharmacogenomics Knowledge Base (PharmGKB), October 2014.**
126. **Cavallari LH,** Duarte JD. Genes affecting warfarin response – interactive or additive? (Invited Commentary) *J Clin Pharmacol* 2015 Mar;55(3):258-260. PMID: 25385663.
127. **Cavallari LH,** Weitzel K. Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. (Invited Commentary) *Future Cardiol* 2015 May;11(3):281-286. PMID: 26021633. PMCID: PMC4477265.
128. Arwood MJ, **Cavallari LH,** Duarte JD. Pharmacogenomics of hypertension and heart disease. (Invited Review) *Curr Hypertens Rep* 2015 Sept;17(9):586. PMCID: PMC4730880.
129. **Cavallari LH,** Mason DL. Cardiovascular pharmacogenomics – implications for patients with CKD. (Invited Review) *Adv Chronic Kidney Dis* 2016 Mar;23(2):82-90. PMCID: PMC4795471.
130. Arwood MJ, Chumnumwat S, **Cavallari LH,** Nutescu ED, Duarte JD. Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges. *Clin Transl Sci* 2016 May [Epub ahead of print] PMID: 27214750.
131. **Cavallari LH,** Lee CR, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, Johnson JA. Implementation of inpatient models of pharmacogenetics programs. (Invited Review) *Am J Health Syst Pharm* 2016 Dec;73(23):1944-1954. PMCID: PMC5359627.

132. **Cavallari LH**, Obeng AO. Genetic determinants of P2Y<sub>12</sub> inhibitors and clinical implications. (Invited Review) *Interv Cardiol Clin* 2017 Jan;6(1):141-149. PMID: PMC5134418.
133. Weitzel KW, **Cavallari LH**, Lesko LJ. Preemptive panel-based pharmacogenetic testing: the time is now. (Invited Review) *Pharm Res* 2017 Aug;34(8):1551-1555. PMID: 28466392. PMID: PMC5518315.
134. **Cavallari LH**, Beitelshes AL, Blake KV, Dressler LG, Duarte JD, Eelsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA. The IGNITE Pharmacogenetics Working Group: An opportunity for building evidence with pharmacogenetic implementation in a real-world setting. *Clin Trans Sci* 2017 May;10(3):143-146. PMID:PMC5421730.
135. **Cavallari LH**. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention (Invited Review). *Expert Rev Cardiovasc Ther* 2017 Aug;15(8):581-589. PMID: 28699807. PMID: PMC5628391.
136. Kaye JB, Schultz LE, Steiner HE, Kittles RA, **Cavallari LH**, Karnes JH. Warfarin pharmacogenomics in diverse populations. *Pharmacotherapy* 2017 Sep;37(9):1150-1163. PMID: 28672100.
137. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, **Cavallari LH**, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin Pharmacol Ther* 2017Sep;102(3):397-404. PMID: 28198005. PMID:PMC5546947.
138. Deng J, Vozmediano V, Rodriguez M, **Cavallari LH**, Schmidt S. Genotype-guided dosing of warfarin through modeling and simulation. (Invited Review) *Eur J Pharm Sci* 2017 Nov 15;109S:S9-S14. PMID: 28502675.
139. Moon JY, Franchi F, Rollini F, Rivas Rios JR, Kureti M, **Cavallari LH**, Angiolillo DJ. Role of genetic testing in patients undergoing percutaneous coronary intervention. *Expert Rev Clin Pharmacol* 2018 Feb;11(2):151-164. PMID: 28689434. PMID: PMC5771818.
140. Smith DM, Weitzel KW, **Cavallari LH**, Eelsey AR, Schmidt SS. Clinical application of pharmacogenetics in pain management (Invited Review). *Per Med* 2018 Mar;15(2):117-126. PMID: 29714124.
141. **Cavallari LH**, Pratt VM. Building evidence for clinical use of pharmacogenomics and reimbursement for testing (Invited Review). *Adv Mol Pathol* 2018; 1(1):125-134. (Inaugural issue).
142. Volpi S, Bult C, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez L, Aronson S, **Cavallari LH**, Denny JC, Dressler L, Johnson JA, Klein TE, Leeder SJ, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV. Research directions in the clinical implementation of



pharmacogenomics – an overview of US programs and projects. *Clin Pharmacol Ther* 2018 May;103(5):778-786. PMID: 29460415. PMCID: PMC5902434.

143. Caudle KE, Gammal RS, Karnes JH, Afanasjeva J, Anderson KC, Barreto EF, Beavers C, Bhat S, Birrer KL, Chahine EB, Ensor CR, Flowers SA, Formea CM, George JM, Gosser RA, Hebert MF, Karaoui LR, Kolpek JH, Lee JC, Leung JG, Maldonado AQ, Minze MG, Pulk RA, Shelton CM, Sheridan M, Smith MA, Soefje S, Tellez-Corrales E, Walko CM, **Cavallari LH**. PRN Opinion Paper: Application of precision medicine across pharmacy specialty areas. *J Am Coll Clin Pharm* 2019;2:288-302.
144. Pratt VM, **Cavallari LH**, Del Tredici AL, Hachad H, Ji Y, Moyer AM, Scott SA, Whirl-Carrillo M, Weck KE. Recommendations for clinical *CYP2C9* genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American Pathologists. *J Mol Diagn* 2019 Sep;21(5):746-755. doi: 10.1016/j.jmoldx.2019.04.003. PMID: 31075510.
145. Pratt VM, **Cavallari LH**, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, Whirl-Carrillo M, Weck KE. Recommendations for clinical warfarin sensitivity genotyping allele selection: a report of the Association for Molecular Pathology. *J Mol Diagn* [In press].
146. Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, **Cavallari LH**, Agundez JAG, Duconge J, Ta M, Lee M, Woodahl EL, Claudio-Campos K, Daly AK, Klein T, Pratt VM, Scott SA, Gaedigk A. PharmVar GeneFocus: *CYP2C19*. [In preparation].

#### Conference Proceeding

147. Sharabiani A, Darabi H, Bress A, **Cavallari L**, Nutescu E, Drozda K. Machine learning based prediction of warfarin optimal dosing for African American patients. *IEEE International Conference on Automation Science and Engineering 2013*; MoET4.4:623-628. DOI: 10.1109/CoASE.2013.6653999

#### Editorials and Letters

148. **(Cavallari) Humma LM**, Adenekan PL. Response to renin-angiotensin system antagonists in hypertensive blacks. (Letter to the Editor) *J Am Coll Cardiol* 2003;42(6):1141. PMID: 13678945.
149. **Cavallari L**, Vaitkus P, Groo V. Hyperkalemia after the Publication of RALES. (Letter to the Editor) *New Engl J Med* 2004;351 (23):2448-2450. PMID: 15580677.
150. **Cavallari LH**. Pharmacogenomics in heart failure: Individualizing therapy based on genotype. (Invited Editorial) *Future Cardiol* 2006;2(2):129-131. PMID: 19804067.
151. **Cavallari LH**.  $\beta$ -adrenergic receptor pharmacogenetics. (Invited Editorial) *Future Cardiol* 2007;3(3):229-232. PMID: 19804212.
152. Momary K, **Cavallari LH**. Clopidogrel and proton pump inhibitors – between a rock and a hard place. (Invited Editorial) *Pharmacotherapy* 2010;30(8):762-765. PMID: 20653351.

153. **Cavallari LH**, Schumock GT. Cost is not a barrier to implementing clopidogrel pharmacogenetics. (Invited Editorial) *Pharmacotherapy* 2012;32(4):299-303. PMID: 22461119.
154. **Cavallari LH**, Perera MA, Kittles RA. Genotype-guided dosing of vitamin K antagonists. (Letter to the Editor) *N Engl J Med* 2014 May;370(18):1763.
155. **Cavallari LH**, Duarte JD. Clopidogrel pharmacogenetics: from evidence to implementation. (Invited Editorial) *Future Cardiol* 2016 Sep;12(5):511-4.
156. **Cavallari LH**. Time to revisit warfarin pharmacogenetics. (Invited Editorial) *Future Cardiol* 2017 Nov;13(6):511-513. PMID: 28967279.
157. **Cavallari LH**, Lee CR. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty. (Invited Editorial) *Future Cardiol* 2019 Jul;15(4):251-254. PMID: 31385522.
158. **Cavallari LH**, Johnson JA. A case for genotype-guided pain management. (Invited Editorial). *Pharmacogenomics* 2019 Jul;20(10):705-708. PMID: 31368851.

#### Books

159. **(Cavallari) Humma LM**, Ellingrod VL, Kolesar JM. Drug Information Series - Pharmacogenomics Handbook. 1<sup>st</sup> ed. Lexi-Comp, Inc: Hudson, OH, 2003.
160. **Cavallari LH**, Ellingrod VL, Kolesar JM. Drug Information Series - Pharmacogenomics Handbook. 2<sup>nd</sup> edition. Lexi-Comp, Inc: Hudson, OH, 2005.
161. Lam YWF, **Cavallari LH** (eds). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc: Maryland Heights, MO. 2013. Companion materials available at [booksite.elsevier.com/9780123919182](http://booksite.elsevier.com/9780123919182).

#### Book Chapters

162. **(Cavallari) Humma LM**, Lam YWF. Pharmacogenetics: Genetic Contribution to Drug Response and an Introduction to Gene Therapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 5<sup>th</sup> ed. McGraw Hill Companies, Inc: New York, 2002. pp. 55-67.
163. **Cavallari LH**. Cardiovascular Pharmacogenomics. In: Allen WL, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, McLeod HL, Spencer HT, Tami JA (eds). *Pharmacogenomic Applications in Patient Care*. 1<sup>st</sup> ed. American College of Clinical Pharmacy: Kansas City, MO, 2004. pp. 495-532.
164. **Cavallari LH**, Shord SS. Pharmacogenomics. In: Schumock GT, Brundage DM, Chapman MM, et al (eds). *Science and Practice of Pharmacotherapy, Book 5, Pharmacotherapy Self-Assessment Program*. 5<sup>th</sup> ed. American College of Clinical Pharmacy: Kansas City, MO, 2005. pp. 189-214.

165. Johnson JA, **Cavallari LH**. Cardiovascular Pharmacogenomics. In: Raizada MK, Paton JFR, Katovich MJ, Kasparov S (eds). Cardiovascular Genomics: Gene Mining for Pharmacogenomics and Gene Therapy. Humana Press, Inc: Totawa NJ, 2005. pp. 71-94.
166. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 6<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2005. pp. 75-90.
167. **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT (eds). Pharmacotherapy Principles & Practice. 1<sup>st</sup> ed. McGraw-Hill Companies, Inc: New York, 2007. pp. 63-82. **\*\*This book received the American Medical Writers Association Distinguished 2008 Medical Book Healthcare Professionals Award.**
168. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 7<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2008. pp. 31-36.
169. Parker RB, Rogers JE, **Cavallari LH**. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 7<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2008. pp. 173-216.
170. **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice. 2<sup>nd</sup> ed. McGraw-Hill Companies, Inc: New York, 2010. pp. 109-129.
171. DiDomenico RJ, **Cavallari LH**. Stable Ischemic Heart Disease. In: Crouch M (ed). Cardiovascular Pharmacotherapy: A Point-of-Care Guide. 1<sup>st</sup> ed. American Society of Health-System Pharmacists, Inc: Bethesda, 2010. pp. 121-142.
172. Shin J, **Cavallari LH**. Warfarin Pharmacogenomics. In: Richardson MM, Hammond Chessman K, Chant C, Finks SW, Hemstreet BA, Hume AL, Hutchison LC, Karpiuk EL, McCollum M, Segarra-Newnham M, Sherer JR (eds). Science and Practice of Pharmacotherapy, Book 5, Pharmacotherapy Self-Assessment Program. 7<sup>th</sup> ed. American College of Clinical Pharmacy: Kansas City, 2011. pp. 51-67.
173. **Cavallari LH**, Peksa G, DiDomenico RJ. Ischemic Heart Disease. In: Katz MD, Matthias KR, Chisholm-Burns MA (eds). Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach. 1<sup>st</sup> ed. McGraw-Hill Companies, Inc: New York, 2011. pp. 31-34.
174. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 8<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2011. pp. 17. Complete chapter, learning objectives, and other resources available at [www.pharmacotherapyonline.com](http://www.pharmacotherapyonline.com).
175. Parker RB, **Cavallari LH**. Systolic Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 8<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2011. pp. 137-172.

176. **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT (eds). *Pharmacotherapy Principles & Practice*. 3rd ed. McGraw-Hill Companies, Inc: New York, 2013. pp. 109-131.
177. Lam FY, **Cavallari LH**. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications. In: Lam YWF, **Cavallari LH** (eds). *Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation*. Elsevier Inc: Maryland Heights, MO. 2013. pp. 1-44.
178. **Cavallari LH**, Klein TE, Huang SM. Governmental and Academic Efforts to Advance the Field of Pharmacogenomics. In: Lam YWF, **Cavallari LH** (eds). *Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation*. Elsevier Inc: Maryland Heights, MO. 2013. pp.63-88.
179. **Cavallari LH**, Momary KM. Pharmacogenetics in Cardiovascular Diseases. In: Lam YWF, **Cavallari LH** (eds). *Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation*. Elsevier Inc: Maryland Heights, MO. 2013. pp. 133-182.
180. **Cavallari LH**, Bress A, DiDomenico LH. Ischemic Heart Disease. In: Katz MD, Matthias KR, Chisholm-Burns MA (eds). *Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach*. 3rd ed. McGraw-Hill Education: New York, 2014. pp. 31-34.
181. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 9<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2014. eChapter available at [www.mhpharmacotherapy.com](http://www.mhpharmacotherapy.com)
182. Parker RB, Nappi J, **Cavallari LH**. Chronic Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 9<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York, 2014. pp. 85-122.
183. **Cavallari LH**, Shin JK. Pharmacogenetics of Anticoagulant Drugs. In: Johnson JA, Ellingrod VL, Kroetz DL, Kuo GM (eds). *Pharmacogenomics: Applications to Patient Care*. 3rd ed. American College of Clinical Pharmacy, Lenexa, 2015. Pp. 79-101
184. DiDomenico RJ, **Cavallari LH**. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT (eds). *Pharmacotherapy Principles & Practice*. 4th ed. McGraw-Hill Companies, Inc: New York, 2016. pp. 91-110.
185. Bress A, **Cavallari LH**, DiDomenico RJ. Ischemic Heart Disease. In: Katz MD, Matthias KR, Chisholm-Burns MA (eds). *Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach*. 4th ed. McGraw-Hill Education: New York, 2016. Pp. 33-35.
186. Gaedigk A, Sangkuhl K, **Cavallari LH**. Pharmacogenetics and Genomics. In: Ye SQ (ed). *Big Data Analysis for Bioinformatics and Biomedical Discoveries*. Chapman & Hall/CRC Press: Boca Raton 2016. Pp. 179-200.

187. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 10<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York 2017. Chapter e5.
188. Parker RB, Nappi J, **Cavallari LH**. Chronic Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 10<sup>th</sup> ed. McGraw-Hill Companies, Inc: New York 2017. Pp. 79-116.
189. **Cavallari LH**, Mosley SA, Johnson JA. Pharmacogenetics. In: Wecker L, Taylor DA, Theobald RJ. *Brody's Human Pharmacology*. 6<sup>th</sup> ed. Elsevier Inc: Philadelphia 2019. Pp. 39-46.
190. **Cavallari LH**, Momary KM. Pharmacogenetics in Cardiovascular Diseases. In: Lam YWF, Scott SA (eds). *Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation*. 2nd ed. Elsevier Inc: San Diego, CA 2019. Pp. 133-179.
191. Parker RB, Nappi J, **Cavallari LH**. Chronic Heart Failure. In: DiPiro JT, Yee GC, Ellingrod VL, Haines ST, Nolin TD, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 11<sup>th</sup> ed. [In press].
192. **Cavallari LH**, Lam YWF. Pharmacogenetics. In: DiPiro JT, Yee GC, Ellingrod VL, Haines ST, Nolin TD, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach*. 11<sup>th</sup> ed. [In press].

### Essays

193. **Cavallari LH**. Unanswered Questions: Pharmacogenomics. In: Russell PJ, Hertz PE, McMillan B (eds). *Biology: The Dynamic Science*. 2<sup>nd</sup> ed. Brooks/Cole, Cengage Learning, Inc, Belmont, CA. 2011. pp.411.
194. **Cavallari LH**. Unanswered Questions: Pharmacogenomics. In: Russell PJ, Hertz PE, McMillan B (eds). *Biology: The Dynamic Science*. 3<sup>rd</sup> ed. Brooks/Cole, Cengage Learning, Inc, Belmont, CA. 2014. Pp. 435-436.
195. **Cavallari LH**. Unanswered Questions: Pharmacogenomics. In: Russell PJ, Hertz PE, McMillan B (eds). *Biology: The Dynamic Science*. 3<sup>rd</sup> ed. Brooks/Cole, Cengage Learning, Inc, Belmont, CA. 2016. Pp. 454.
196. **Cavallari LH**. Unanswered Questions: Pharmacogenomics. In: Russell PJ, Hertz PE, McMillan B (eds). *Biology: The Dynamic Science*. 5<sup>th</sup> ed. Brooks/Cole, Cengage Learning, Inc, San Francisco, CA. [In press].

### **ABSTRACTS AND SCIENTIFIC PRESENTATIONS**

1. **(Cavallari) Humma LM**, Farmerie WG, Wallace MR, Johnson JA.  $\beta_2$ -adrenoceptor polymorphisms and hypertension. *Pharmacotherapy* 1999;19:1193 (#5). Platform presentation at the 20<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacy, Kansas City, MO. October 1999. **\*\*First runner-up in the Best Student, Resident, Fellow Paper Award Competition.**

2. **(Cavallari) Humma LM**, Richardson HE, Lewis JF, Pepine CJ, Johnson JA. Dobutamine pharmacodynamics. *Clin Pharmacol Ther* 2000;67:117. Poster presentation at the 101<sup>st</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Los Angeles, CA. March 2000.
3. **(Cavallari) Humma LM**, Nguyen BN, Farmerie WG, Wallace MR, Johnson JA.  $\beta_2$ -adrenoceptor polymorphisms are associated with nocturnal blood pressure decline in hypertensives. *J Am Coll Cardio*. 2000;35(Suppl A):333A (#1204-23). Poster presentation at the 49<sup>th</sup> Annual Session of the American College of Cardiology, Anaheim, CA. March 2000.
4. **(Cavallari) Humma LM**, Richardson HE, Puckett BJ, Lejeune BL, Farmerie WG, Wallace MR, Lewis JF, McNamara DM, Pepine CJ, Johnson JA. Functional significance of  $\beta_1$ -adrenergic receptor polymorphisms in humans. *J Cardiac Failure* 2000;6(Suppl 2):29 (#109). Poster presentation at the 4<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America, Boca Raton, FL. September 2000.
5. **(Cavallari) Humma LM**, Nguyen NB, Wallace MR, Farmerie WG, Johnson JA.  $\beta_1$ - and  $\beta_2$ -adrenergic receptor polymorphisms and diurnal blood pressure variation. *Pharmacotherapy* 2000;20(10):1262-1263 (#206). Poster presentation at the 21<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA. November 2000. **\*\*Winner of the Best Student, Resident, Fellow Paper Award Competition and First Runner-up in the Best Overall Paper Award Competition.**
6. **(Cavallari) Humma LM**, Richardson HE, Lewis JF, Pepine CJ, Johnson JA. Dobutamine Pharmacodynamics. Encore poster presentation at the 21st Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA. November 2000.
7. Puckett BJ, **(Cavallari) Humma LM**, Lejeune BL, Lewis JF, Pepine CJ, Johnson JA. Effects of  $\beta$ -adrenoceptor polymorphisms on resting hemodynamics and dobutamine response in humans. *Pharmacotherapy* 2000;20(10):1262 (#203). Poster presentation at the 21<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA. November 2000. **\*\*First runner-up in the Best Student, Resident, Fellow Paper Award Competition.**
8. **(Cavallari) Humma LM**, BJ Puckett, Lejeune BL, McNamara DM, Pepine CJ, Johnson JA.  $\beta_1$ -adrenergic receptor polymorphisms and obesity. *Clin Pharmacol Ther* 2001;69:P63 (#OII-A-3). Platform presentation at the 102<sup>nd</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Orlando, FL. March 2001.
9. Wang J, **(Cavallari) Humma L**, Mougey E, David CJ, Johnson JJ, Lima JJ, Sylvester J. Determination of  $\beta_2$ -adrenergic receptor haplotype by denaturation selective amplification and subtractive genotyping. *Amer J Hum Gene* 2001;69:542. Poster presentation at the 51<sup>st</sup> Annual Meeting of the American Society of Human Genetics. October 2001.
10. Aquilante C, **(Cavallari) Humma L**, Andrisin T, Lejeune B, Lewis J, Hamilton K, Johnson J. The influence of gender and race on pharmacodynamic response to dobutamine during dobutamine stress echocardiography. *Clin Pharmacol Ther* 2002;71(2):P80. Poster presentation at the 103<sup>rd</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Atlanta, GA. March 2002.

11. Nutescu E, **(Cavallari) Humma LM**, Fashingbauer LA, Pham C, Helgason CM. Factors influencing the activity of antiplatelet agents in stroke patients. *Pharmacotherapy* 2002; 22(3):406 (#16). Poster presentation at the 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.
12. **(Cavallari) Humma LM**, Fashingbauer LA, Beitelshes AL, Just VL, Southworth MR, Williams RE, Dunlap S. Effects of race and gender on potassium requirements with spironolactone therapy in heart failure. *J Cardiac Fail* 2002;8(4):S60 (P218). Poster presentation at the 6<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America. Boca Raton, FL. September 2002.
13. Beitelshes AL, Bauman JL, Southworth MR, DiDomenico RJ, Dunlap SH, Fashingbauer LA, **(Cavallari) Humma LM**. Cost savings associated with a decreased need for potassium supplementation in heart failure patients on spironolactone. *Pharmacotherapy* 2002; 22(10):1327 (#20). Platform presentation at the 2002 Annual Meeting of the American College of Clinical Pharmacy. Albuquerque, NM. October 2002.
14. Aquilante CL, **(Cavallari) Humma LM**, Terra SG, Andrisin TM, Lewis JF, Hamilton KK, Walker JR, Picoult-Newberg L, Johnson JA. Adrenergic receptor polymorphisms and response to dobutamine. *Pharmacotherapy* 2002; 22(10):1362 (#240). Poster presentation at the 2002 Annual Meeting of the American College of Clinical Pharmacy. Albuquerque, NM. October 2002. **\*\*First runner-up in the Best Student, Resident, Fellow Paper Award Competition.**
15. **(Cavallari) Humma LM**, Young LF, Geenen, DL. Aldosterone-mediated effects vary between rats with different angiotensinogen genotypes. *Pharmacotherapy* 2003; 23(10):1358 (#206). Platform presentation at the 2003 Annual Meeting of the American College of Clinical Pharmacy. Atlanta, GA. November 2003.
16. **(Cavallari) Humma LM**, Helgason CM, Zhong E, Shapiro N, Young L, Nutescu E. Glycoprotein IIIa genotype and aspirin response in stroke. *Stroke* 2004;35(1):235 (#3). Platform presentation at the American Stroke Association 29<sup>th</sup> International Stroke Conference. San Diego, CA. February 2004.
17. Chan L, **(Cavallari) Humma LM**, Schriever CA, Fashingbauer LA, Domingez CP, Baum CL. Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-GP) in humans. *Clin Pharmacol Ther* 2004;75(2):P95. Poster presentation at the 105<sup>th</sup> Meeting of the American Society of Clinical Pharmacology and Therapeutics. Miami Beach, FL. March 2004.
18. Beitelshes AL, **Cavallari LH**, Gaston KG, Okorochnikwu TU, Johnson JA. Beta1-adrenergic receptor polymorphisms and hypertension. *Clin Pharmacol Ther* 2004;75(2):P61. Poster presentation at the 105<sup>th</sup> Meeting of the American Society of Clinical Pharmacology and Therapeutics. Miami Beach, FL. March 2004.
19. Belgado BS, **Cavallari LH**, Langae T, Okorochnikwu T, Sloan A, Johnson JA. Association of Beta2-adrenergic receptor ( $\beta$ 2AR) haplotype and hypertension in African Americans and Caucasians. *Clin Pharmacol Ther* 2004;75(2):P95. Poster presentation at the 105<sup>th</sup> Meeting of the American Society of Clinical Pharmacology and Therapeutics. Miami Beach, FL. March 2004.

20. Molokie RE, **Cavallari LH**, Pawlak KR, Shord SS. Interpatient variability in analgesic response to codeine and hydrocodone in sickle cell disease. *Proc Am Soc Clin Oncol* 2004;23: #2089
21. Momary KM, Fashingbauer LA, Shapiro NL, Nutescu E, Helgason CM, Pandey DK, **Cavallari LH**. Demographic and environmental influences of warfarin response in African Americans. *Pharmacotherapy* 2004;24(10):1423 (#23). Platform presentation at the 2004 Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 2004.
22. **Cavallari LH**, Fashingbauer LA, Groo V, Southworth MR, Fontana D, Williams RE, Vaitkus P. Racial differences in potassium response to spironolactone. *Pharmacotherapy* 2004;24(10):1423-1424 (#24). Platform presentation at the 2004 Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 2004.
23. Mathew S, Sweiss K, Ahmed H, Radwanski P, **Cavallari L**. American College of Clinical Pharmacy (ACCP) Survey: Assessment of student interest in clinical pharmacy. *Pharmacotherapy* 2004;24(10):1480 (#408). Poster presentation at the 2004 Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 2004.
24. Krueger C, Rene L, Momary K, Groo V, Fontana D, Vaitkus P, **Cavallari L**. Dietary potassium intake and potassium use with spironolactone. *Pharmacotherapy* 2005;25(10):1437 (#44). Poster presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA. October 2005.
25. Momary K, Shapiro NL, Nutescu EA, Helgason CM, Cavallari L. Vitamin K reductase genotype and warfarin dose requirements. *Pharmacotherapy* 2005;25(10):1480 (#298). Poster presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA. October 2005.
26. Master H, Groo V, **Cavallari L**, Shroff A. Racial differences in the prevalence of atrial fibrillation in heart failure: a retrospective review. *Pharmacotherapy* 2005;25(10):1495 (#393). Poster presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA. October 2005.
27. Momary KM, Nutescu EA, Shapiro NL, Viana MA, Helgason CM, **Cavallari LH**. Vitamin K epoxide reductase complex 1 polymorphism and warfarin dose in African Americans. *Clin Pharmacol Ther* 2006;79(2):P32 (#OIV-A-3). Platform presentation at the 2006 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics (ASCPT). Baltimore, MD. March 2006. **\*\*Dr. Momary was selected for an ASCPT Presidential Trainee Award in recognition of this abstract.**
28. Groo VL, Momary KM, Stamos TD, Camp JR, **Cavallari LH**. Serum procollagen peptides are similar in mildly and severely symptomatic patients with heart failure. *J Cardiac Fail* 2006;12(6):S32 (P103). Poster presentation at the 10<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America. Seattle, WA. September 2006.
29. Perez A, **Cavallari LH**, Fontana D, Stamos TD, Groo VL. Low dose aldosterone antagonism reduces diuretic requirements in heart failure. *J Cardiac Fail* 2006;12(6):S118 (P387). Poster presentation at the 10<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America. Seattle, WA. September 2006.



30. Momary KM, Groo VL, Stamos TD, Camp JR, **Cavallari LH**. Beta-blocker dose influences cardiac response to spironolactone in heart failure. *Pharmacotherapy* 2006; 26:e55 (#40). Poster presentation at the 2006 Annual Meeting of the American College of Clinical Pharmacy. St. Louis, MO. October 2006. **\*\*First runner-up in the Best Student, Resident, Fellow Paper Award Competition.**
31. Momary KM, Shapiro NL, Brace LD, Shord SS, Viana MA, Helgason CM, Nutescu EM, **Cavallari LH**. The influence of cyclooxygenase-1 and glycoprotein IIIa genotypes on aspirin response. *Clin Pharmacol Ther* 2007; 81 (Suppl 1):S93 (#PIII-24). Poster presentation at 108th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Anaheim, CA. March 2007.
32. Aston JL, Momary KM, Shapiro NL, **Cavallari LH**. Influences of International Normalized Ratio fluctuation in African Americans taking warfarin. *Pharmacotherapy* 2007; 27(4):e36 (#183). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Poster presentation at the 2007 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Memphis, TN. April 2007.
33. **Cavallari LH**, Groo VL, Momary KM, Stamos TD. Angiotensinogen diplotype and spironolactone response in heart failure. *J Cardiac Fail* 2007;13(6):S100 (#253). Poster presentation at the 11th Annual Scientific Meeting of the Heart Failure Society of America. Washington, DC. September 2007.
34. **Cavallari LH**, Groo VL, Stamos TD. Markers of cardiac fibrosis are similar in African Americans and Caucasians with heart failure. *J Cardiac Fail* 2007;13(6):S100 (#091). Poster presentation at the 11th Annual Scientific Meeting of the Heart Failure Society of America. Washington, DC. September 2007.
35. Momary KM, Shapiro NL, Brace L, Shord SS, Viana MAG, Helgason CM, Nutescu EA, **Cavallari LH**. Comparison of two laboratory methods for measuring aspirin inhibition of platelet aggregation. *Pharmacotherapy* 2007;27 (10):e195 (#36). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Platform presentation at the 2007 Annual Meeting of the American College of Clinical Pharmacy. Denver, CO. October 2007.
36. Momary KM, Shapiro NL, Viana MAG, Nutescu EA, Helgason CM, **Cavallari LH**. Association between CYP2C9 genotype and warfarin dose requirements in African Americans. *Pharmacotherapy* 2007;27 (10):e218 (#89). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Platform presentation at the 2007 Annual Meeting of the American College of Clinical Pharmacy. Denver, CO. October 2007.
37. Momary KM, Shapiro NL, Nutescu EA, Brace LD, Shord SS, Helgason CM, **Cavallari LH**. The influence of cyclooxygenase-1 A-707G and C50T polymorphisms on aspirin response. *Clin Pharmacol Ther* 2008; 83 (Suppl 1):S48 (#PII-20). Poster presentation at 2008 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL. April 2008.
38. Shord SS, **Cavallari LH**, Viana MA, Momary K, Molokie RE, Neceskas J. Cytochrome P450 2C9 (CYP2C9) metabolic capacity in people with and without cancer. *Clin Pharmacol Ther* 2008; 83 (Suppl 1):S50 (#PII-27). Poster presentation at 2008 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL. April 2008.

39. Shord SS, Molokie RE, **Cavallari LH**, Gao W, Jeong H. Cytochrome P450 (CYP) 2D6 influences codeine metabolism in sickle cell disease (SCD). *Clin Pharmacol Ther* 2008; 83 (Suppl 1):S51 (#PII-28). Poster presentation at 2008 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL. April 2008.
40. **Cavallari LH**, Groo VL, Viana, MA, Camp JR, Stamos TD. Angiotensinogen haplotype and potassium response to spironolactone. *Clin Pharmacol Ther* 2008; 83 (Suppl 1):S81 (#PIII-31). Poster presentation at 2008 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL. April 2008.
41. Goodwin H, Groo V, **Cavallari L**, Stamos T. Late onset hyperkalemia with spironolactone therapy. *J Cardiac Fail* 2008; 14(6):S113 (#372). Poster presentation at the 12<sup>th</sup> Annual Scientific meeting of the Heart Failure Society of America. Toronto, ON, Canada. September 2008.
42. **Cavallari LH**, Groo VL, Patel S, Viana MAG, Stamos TD. Circulating aldosterone is predictive of potassium elevations with spironolactone in heart failure. *J Cardiac Fail* 2008; 14(6):S74 (#235). Poster presentation at the 12th Annual Scientific meeting of the Heart Failure Society of America. Toronto, ON, Canada. September 2008.
43. Hoeksema J, **Cavallari L**, Groo V, Avitall B, Gonzalez R. Effect of aldosterone antagonists on shock frequency with implantable cardioverter defibrillators. *J Cardiac Fail* 2008; 14(6):S75 (#240). Poster presentation at the 12th Annual Scientific meeting of the Heart Failure Society of America. Toronto, ON, Canada. September 2008.
44. **Cavallari LH**, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. Circulating aldosterone and mineralocorticoid receptor genotype are predictive of potassium response to spironolactone in heart failure. *Pharmacotherapy* 2008; 28:120e (#18). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Platform presentation at the 2008 Annual Meeting of the American College of Clinical Pharmacy. Louisville, KY. October 2008.
45. **Cavallari LH**, Momary KM, Shapiro NL, Nutescu EA, Patel SR, Viana MAG. Vitamin K epoxide reductase genotype is associated with warfarin dose requirements in Hispanics. *Pharmacotherapy* 2008; 28:172e (#192). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Platform presentation at the 2008 Annual Meeting of the American College of Clinical Pharmacy. Louisville, KY. October 2008.
46. Momary KM, Bishop J, Shapiro NL, Nutescu EA, Brace LD, Shord SS, Helgason CM, **Cavallari LH**. Influence of serotonin transporter genotype on aspirin response. *Pharmacotherapy* 2008; 28:174e (#198). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Platform presentation at the 2008 Annual Meeting of the American College of Clinical Pharmacy. Louisville, KY. October 2008.
47. **Cavallari LH**, Momary KM, Shapiro NL, Nutescu EA, Patel SR, Viana MAG. Genetic and clinical determinants of warfarin dose requirements in African Americans. *Pharmacotherapy* 2009; 29:61e (#96). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Platform presentation at the 2009 American College of Clinical Pharmacy/European Society of Clinical Pharmacy International Congress on Clinical Pharmacy. Orlando, FL. April 27, 2009. \*\*\***Winner of the Best Paper Competition.**

48. Butler CP, Patel SR, Langaee TY, Nutescu EA, Shapiro NL, **Cavallari LH**. Apolipoprotein E genotype influences time to stable warfarin dosing. *Pharmacotherapy* 2009; 29(10):232e (#175). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Moderated poster presentation at the 2009 Annual Meeting of the American College of Clinical Pharmacy. Anaheim, CA. October 20, 2009. **\*\*Second runner up in the Best Resident and Fellow Poster Competition.**
49. Perera MA, **Cavallari LH**, Patel S, Ramikie T, Flynn M, Cox NJ. A pharmacogenetic study of novel SNPs in *VKORC1* and *CYP2C9* in an African American cohort: implications in warfarin maintenance dose. (#2230) Poster presentation at the 59<sup>th</sup> Annual Meeting of the American Society of Human Genetics. Honolulu, Hawaii. October 22, 2009.
50. Anderson A, Limdi M, **Cavallari L**, Baird M, Allon M, Beasley M, Limdi N. Warfarin dosing in patients with impaired renal function. *Am J Kidney Dis* 2010;55(4):A75. Presented at the National Kidney Foundation Spring Clinical Meeting. Washington DC. May 2010.
51. Blekhman Y, Patel SR, Groo VL, Stamos TD, **Cavallari LH**. Aldosterone escape in heart failure and atrial natriuretic peptide precursor A (*NPPA*) genotype. *Pharmacotherapy* 2010; 30:207e (#209). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Moderated poster presentation at the 2010 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Charlotte, NC. April 24, 2010. **\*\*Finalist in the Best Student Poster Competition.**
52. **Cavallari LH**, Patel SR, Groo VL, Viana MA, Stamos TD. Association between angiotensinogen genotype and aldosterone levels in heart failure. *Pharmacotherapy* 2010; 30:166e (#52). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Poster presentation at the 2010 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Charlotte, NC. April 26, 2010.
53. Taube G, Shapiro NL, Nutescu EA, Patel SR, Viana MA, **Cavallari LH**. *CALU* and *GGCX* genotype associations with warfarin dose requirements in African Americans. *Pharmacotherapy* 2010; 30:207e (#210). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Moderated poster presentation at the 2010 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Charlotte, NC. April 26, 2010. **\*\*First runner-up in the Best Student Poster Competition.**
54. **Cavallari LH**, Patel SR, Blekhman Y, Groo VL, Stamos TD. *NPPA* genotype is associated with aldosterone breakthrough in heart failure. *J Cardiac Fail* 2010; 16(8S):S38 (#116). Poster presentation at the 14th Annual Scientific Meeting of the Heart Failure Society of America. San Diego, CA. September 12-15, 2010.
55. Cochran KA, Bishop JR, **Cavallari LH**, Shapiro NL. Bleeding incidence and risk evaluation with concomitant use of antidepressants and warfarin. *Pharmacotherapy* 2010; 30:369e (#14). Available through [www.pharmacotherapy.org](http://www.pharmacotherapy.org). Moderated poster at the 2010 Annual Meeting of the American College of Clinical Pharmacy. Austin, TX. October 2010. **\*\*First place Ambulatory Care PRN Walk Rounds and first runner-up in the Best Resident & Fellow Poster competition.**
56. Lindley KJ, Limdi N, **Cavallari LH**, Perera M, Lenzini P, Johnson J, Wu A, Ridker PM, Patel S, King C, Shah S, Eby CS, Beasley TM, Gage BF. Warfarin dosing in patients with the

- CYP2C9\*5* variant. *Circulation* 2010; 122(21 Suppl):A16860. Presented at the 2010 American Heart Association Scientific Session. Chicago, IL. November 2010.
57. **Cavallari L**, Drozda K, Perera M, Patel S, Shapiro N, Nutescu E, Stamos T. Association between *CYP2C9* promoter region variants and warfarin dose requirements in African Americans. *Clin Pharmacol Ther* 2011;89 (Suppl 1):S77 (#PIII-33). Poster presentation at American Society for Clinical Pharmacology and Therapeutics 2011 Annual Meeting. Dallas, TX. March 2011.
58. Nutescu E, Sharp L, Bathija S, Dotiwala Z, **Cavallari L**, Schumock G, Meltzer D, Fitzgibbon M. Factors that Influence Adoption of Anticoagulation Self-Monitoring in Underserved Minority Patients. *J Thromb Thrombolysis* 2011;31(3):382-D8. Poster presentation at the Anticoagulation Forum Meeting. Boston, MA. May 2011.
59. **Cavallari LH**, Perera M, Taube G, Patel SR, Aquino-Michaels K, Viana MAV, Shapiro NL, Nutescu EA. Association of the gamma-glutamyl carboxylase (CAA)16/17 repeat polymorphism with higher warfarin dose requirements African Americans. *Pharmacotherapy* 2011;31:371e (#219). Platform presentation at the 2011 Annual Meeting of the American College of Clinical Pharmacy. Pittsburgh, PA. October 18, 2011.
60. Drozda K, Takahashi H, Patel SR, Shapiro NL, Nutescu EA, **Cavallari LH**. Association between the *CYP2C9\*8* variant and warfarin clearance in African Americans. *Pharmacotherapy* 2011;31:436e (#459). Poster presentation at the 2011 Annual Meeting of the American College of Clinical Pharmacy. Pittsburgh, PA. October 17, 2011.
61. Gleason TE, Shapiro NL, **Cavallari LH**, Nutescu EA, Kominiarek M, Hibbard JU. Use of low molecular weight heparin (LMWH) in pregnancy: a pharmacodynamic modeling study. *Pharmacotherapy* 2011;31:316e (#17). Poster presentation at the 2011 Annual Meeting of the American College of Clinical Pharmacy. Pittsburgh, PA. October 17, 2011.
62. Bress AP, Groo VL, DiDomenico RJ, Stamos TD, Viana M, Patel S, **Cavallari LH**. The effect of epithelial sodium genotype on loop diuretic requirements in systolic heart failure - interim analysis of the first 50 subjects. *Pharmacotherapy* 2011;31:415e-416e (#381). Resident research in progress poster presentation at the 2011 Annual Meeting of the American College of Clinical Pharmacy. Pittsburgh, PA. October 18, 2011.
63. Groo VL, Williams KM, **Cavallari LH**, Stamos TD. Determinants of worsening renal function with diuretic dose escalation in a chronic heart failure ambulatory population. *Pharmacotherapy* 2011;31:322e (#39). Poster presentation at the 2011 Annual Meeting of the American College of Clinical Pharmacy. Pittsburgh, PA. October 18, 2011.
64. Perera MA, Limdi NA, **Cavallari L**, Gamazon ER, Konkashbaev A, Pluzhnikov A, Wang J, Liu N, Wagner MJ, Wu A, Roden DM, Crawford DC, Burmester JK, Evertson J, Tector M, Mushiroda T, Kubo M, Altman RB, Klein TE, Rieder MJ, Nakamura Y, Cox NJ, Johnson JA, for the International Warfarin Pharmacogenetics Consortium. Novel SNPs associated with warfarin dose in a large multicenter cohort of African Americans: Genome wide association study and replication results. *Circulation* 2011; 124: Supplement 1 (#15518) Platform presentation at the 2011 American Heart Association Scientific Session. Orlando, FL. November 2011.

65. Bress A, Groo V, DiDomenico R, Stamos T, **Cavallari L**. The effect of race and genetic variants of the renal sodium transporters on diuretic requirements in patients with systolic heart failure. 2011 American Society of Health-System Pharmacists Midyear Clinical Meeting. New Orleans, LA. December 2011.
66. Bathija S, Schumock GT, Sharp LK, Gerber BS, Fitzgibbon ML, **Cavallari LH**, Nutescu EA. Patient factors affecting non-adherence to anticoagulation therapy in an inner-city underserved minority population. *Value in Health* 2012;15(4):A126-PCV76. Poster presentation at the ISPOR 17th Annual International Meeting. Washington DC. June 2012.
67. Nutescu E, **Cavallari L**, Galanter W, Kadkol S, Dodge C, Stamos T, Krishnan JA, Becker B, Darabi H, Garcia JGN. Implementation of a multidisciplinary warfarin pharmacogenetics service at the University of Illinois Hospital & Health Sciences System (UI-Health). *Pharmacotherapy* 2012;31:271e (#316). Poster presentation at the 2012 Annual Meeting of the American College of Clinical Pharmacy. Hollywood, FL. October 2012.
68. Bress A, Patel S, Perera M, Campbell R, Kittles R, **Cavallari L**. The effect of NAD(P)H dehydrogenase, quinone 1 (*NQO1*) genotype on warfarin dose requirements in Hispanic and African Americans. *Pharmacotherapy* 2012;31:233e (#188). Platform presentation at the 2012 Annual Meeting of the American College of Clinical Pharmacy. Hollywood, FL. October 2012. **\*\*First runner-up in the Best Resident and Fellow Poster competition.**
69. Daneshjou R, Aquino-Michaels K, Burkley B, **Cavallari LH**, Johnson JA, Johnson NA, Klein TE, Karczewski KJ, Langaee T, Patel SR, Perera M, Sagreiya H, Tang H, Tatonetti N, Altman RB. Whole exome analysis of African American warfarin pharmacogenomics. Poster presentation at the American Society of Human Genetics meeting. San Francisco, CA. November 2012.
70. Gamazon ER, Daneshjou R, **Cavallari LH**, Limdi NA, Wadelius M, Johnson JA, Klein TE, Scott SA, Tsunoda T, Deloukas P, Altman R, Cox N, Perera MA. Expression quantitative trait loci analysis of stable warfarin dose identifies novel associations: finding signal within the noise. *Clin Pharmacol Ther* 2013;93 (Suppl 1):S27 (#PI-38). Presentation at the American Society of Clinical Pharmacology and Therapeutics 2013 Annual Meeting. Indianapolis, IN. March 2013.
71. Shahin MD, Khalifa SI, Dvorak A, Langaee T, Patel S, Perry K, Perera A, **Cavallari LH**, McLeod HL, Johnson JA. *VKORC1* Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Clin Pharmacol Ther* 2013;93 (Suppl 1):S8 (#PT-10). Poster presentation at the 2013 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. Indianapolis, IN. March 6, 2013. **\*\*Dr. Shahin was selected for an ASCPT Presidential Trainee Award in recognition of this abstract.**
72. Hernandez W, Perera MA, Gamazon ER, Perry K, Aquino-Michaels K, Patel S, O'Brien T, Harralson A, Nicolae D, **Cavallari L**. A novel pharmacogenomics dosing algorithm for African Americans taking warfarin: able to predict where IWPC's algorithm cannot. *Clin Pharmacol Ther* 2013;93 (Suppl 1):S12 (#PT-19). Poster presentation at the 2013 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. Indianapolis, IN. March 6, 2013. **\*\*Dr. Hernandez was selected for an ASCPT Presidential Trainee Award in recognition of this abstract.**

73. Vardeny O, **Cavallari L**, Claggett B, Rossignol P, Zannad F, Pitt B, Solomon SD. Safety and efficacy of spironolactone in African Americans from the Randomized Aldactone Evaluation Study. Moderated poster at the American College of Cardiology 62<sup>nd</sup> Annual Scientific Session, San Francisco, CA. March 9, 2013. **\*\*Awarded Best CAA Poster, representing top 3% of poster acceptances.**
74. Bress A, Patel S, Desai AA, Mansour I, Groo V, Han J, Progar K, Shah E, Stamos T, Kittles R, **Cavallari L**. Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) with atrial fibrillation in African-Americans with heart failure. Poster presentation at the American College of Cardiology 62<sup>nd</sup> Annual Scientific Session, San Francisco, CA. March 10, 2013. **\*\*Awarded Best CAA Poster, representing top 3% of poster acceptances.**
75. Perera MA, Daneshjou R, Gamazon ER, Hillenmeyer S, Karczewski K, Klein TE, Langaee T, Drozda K, Patel S, Johnson JA, **Cavallari LH**, Altman RB. Polyglutamate synthetase (*FPGS*) and warfarin: discovery of genes outside of *CYP2C9* and *VKORC1* through exome analysis. Pharmacogenomics Research Network Scientific Meeting, University of Chicago, Chicago IL. April 2013.
76. Kim K, Calabrese M, Lin FJ, Ojo O, **Cavallari LC**, Touchette DR. Cost-effectiveness of ticagrelor in patients with acute coronary syndrome. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. New Orleans, LA. May 20, 2013.
77. Cheng WH, Galanter W, Schumock G, Lambert B, **Cavallari L**, Nutescu EA. The impact of race on quality of anticoagulation after major orthopedic surgery in an inner-city underserved population. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. New Orleans, LA. May 20, 2013.
78. Drozda K, Nutescu EA, Bress AP, Galanter WL, Stevenson J, Duarte J, **Cavallari LH**. Description and feasibility of a comprehensive warfarin pharmacogenetics service. *Pharmacotherapy* 2013;33(10):e269 (#289). Poster presentation at the 2013 Annual Meeting of the American College of Clinical Pharmacy. Albuquerque NM. October 14, 2013.
79. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien T, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, **Cavallari LH**, Perera MA. *VKORC1* and *CALU* eQTLs and susceptibility to venous thromboembolism among African Americans. Presented at the 63rd American Society of Human Genetics Annual Meeting, Boston, MA, October 22-26, 2013.
80. Duncan M, Bress A, **Cavallari L**, Nutescu E, Drozda K, Galanter W. Clinical decision support for initial dosing of warfarin and promotion of pharmacogenetic testing. Poster presentation at the American Medical Informatics Association 2013 Annual Symposium, Washington DC, November 16-22, 2013.
81. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AR, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Konkashbaev A, **Cavallari LH**, Perera MA. Identification of novel genetic polymorphisms associated with warfarin dose response in African Americans through the use of liver eQTLs. Oral presentation at the Cold Spring

Harbor Laboratory Conference, Precision Medicine: Personal Genomes & Pharmacogenomics meeting. November 13, 2013.

82. Patel R, Drozda K, Lee YM, Nutescu E, **Cavallari LH**. Influence of cytochrome P4502C9 and vitamin k epoxide reductase complex subunit one variants on time to achieve first therapeutic international normalized ratio. Poster presented at 2013 American Society of Health-System Pharmacists Midyear Clinical Meeting. Orlando, FL. December 10, 2013.
83. McDowell M, Patel R, **Cavallari LH**, Drozda K, Nutescu E. The impact of a pharmacist-guided pharmacogenetics service on prediction of warfarin stable dose. Poster presented at 48<sup>th</sup> Annual American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition. Orlando, FL. December 10, 2013.
84. Goncharenko A, **Cavallari LH**, Patel SR, Vardeny O, Sweitzer NK. Epithelial sodium channel genotype and risk for hyperkalemia with an aldosterone antagonist in heart failure. Poster presented at the 48<sup>th</sup> Annual American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition. Orlando, FL. December 10, 2013.
85. Lee YM, Drozda K, Stevenson J, Galanter WL, Stamos TD, Nutescu EA, **Cavallari LH**. Clinical factors affecting time to target INR in genotype-guided warfarin dosing of inpatients. Poster presented at 48<sup>th</sup> Annual American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition. Orlando, FL. December 11, 2013.
86. Drozda K, Wong S, Patel S, Nutescu E, **Cavallari LH**. Effects of African-specific genetic variation on performance of warfarin pharmacogenetic dosing algorithms. *Clin Pharmacol Ther* 2014;95(Suppl 1):S11 (#PT-012). Poster presentation at the 2014 annual meeting of the American Society of Clinical Pharmacology and Therapeutics. Atlanta, GA. March 19, 2014. **\*\*Dr. Drozda was selected for an ASCPT Presidential Trainee Award in recognition of this abstract.**
87. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson RA, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, **Cavallari LH**, Perera M. Liver eQTLs for warfarin dose response genes reveal susceptibility to venous thromboembolism among African Americans. *Clin Pharmacol Ther* 2014;95(Suppl 1):S60 (#OII-C-4). Oral presentation at the 2014 annual meeting of the American Society of Clinical Pharmacology and Therapeutics. Atlanta, GA. March 21, 2014. **\*\*W. Hernandez was selected for an ASCPT Presidential Trainee Award in recognition of this abstract.**
88. Kim K, Ardati AK, DiDomenico RJ, **Cavallari LH**, Touchette DR. Cost-effectiveness of genotype/phenotype driven ticagrelor versus clopidogrel selection in patients with acute coronary syndrome. *J Am Coll Cardiol* 2014;63(12\_S); doi:10.1016/S0735-1097(14)60024-3. Oral presentation at the American College of Cardiology 63<sup>rd</sup> Annual Scientific Session, Washington, DC. March 2014.
89. Cheng WH, Manzoor BS, Cavallari L, Sharp L, Gerber B, Fitzgibbon MI, Schumock GT, Nutescu EA. Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 19<sup>th</sup> Annual International Meeting, Montreal QC, Canada. June 3, 2014. *Value in Health* 2014;17(3):A126-A127;PHS10.

90. Sarangpur S, Sharp L, Berber B, Schumock G, Fitzgibbon M, **Cavallari L**, Bathija Sc, Nutescu E. The impact of missed clinic appointments on the quality of anticoagulation control in an inner-city underserved minority population. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 19<sup>th</sup> Annual International Meeting, Montreal QC, Canada. June 3, 2014. *Value in Health* 2014;17(3):A151;PHS152.
91. Mansour IN, Kansal M, Ismail S, Groo V, Patel S, Bress A, Marpadga R, **Cavallari L**, Stamos TD. Serum N-terminal procollagen III propeptide correlates with left ventricular global longitudinal strain in African Americans with heart failure. Poster presentation at the American Society of Echocardiography Annual Scientific Meeting. Portland OR. June 20-23, 2014.
92. Mansour IN, Kansal M, Ismail S, Mirza O, Bress A, Wu G, **Cavallari L**, Stamos TD. Left ventricular global longitudinal strain predicts heart failure admissions in African American patients. Poster presentation at the American Society of Echocardiography Annual Scientific Meeting. Portland OR. June 20-23, 2014.
93. Mansour IN, Kansal M, Ismail S, Mirza O, Bress A, Wu G, Marpadga R, Li Y, **Cavallari L**, Stamos T. Left ventricular global longitudinal strain predicts mortality in African Americans with heart failure. *J Cardiac Fail* 2014;20(10). Poster presentation at the Heart Failure Society of America Annual Scientific Meeting. Las Vegas, NV. September 14-17, 2014.
94. Mansour IN, Ismail S, Bress A, Groo V, Patel S, Heith H, Stamos T, **Cavallari L**. Serum N-terminal procollagen III propeptide predicts all-cause mortality in African American patients with heart failure. *J Cardiac Fail* 2014;20(10). Poster presentation at the Heart Failure Society of American, Annual Scientific Meeting. Las Vegas, NV. September 14-17, 2014.
95. Daneshjou R, **Cavallari LH**, Karczewski KJ, Drozda D, Perera MA, Johnson JA, Klein TE, Weeke PE, Roden D, Altman RB. Single nucleotide polymorphism confers 4-fold risk of venous thromboembolism in African Americans. Hot Topic Presentation at the Pharmacogenomics Research Network scientific Meeting. Rochester, MN. September 11, 2014.
96. Lee Y, Drozda K, Hoop J, Duarte JD, Nutescu EA, **Cavallari LH**. Barriers to implementing pharmacogenetic testing in an urban population. *Pharmacotherapy* 2014;34(10):e252 (#287). Poster presentation at the 2014 Annual Meeting of the American College of Clinical Pharmacy, Austin TX. October 13, 2014.
97. Drozda K, Patel SR, Nutescu EA, **Cavallari L**. Addition of *CYP2C9*\*5, \*6, \*8, \*11 and rs12777823 genotypes into an existing warfarin dosing algorithm improves algorithm performance for African Americans. *Pharmacotherapy* 2014;34(10):e220 (#168). Poster presentation at the 2014 Annual Meeting of the American College of Clinical Pharmacy, Austin TX. October 15, 2014.
98. Gratie D, Cheng W, Drozda K, Duarte J, Lee J, Galanter WL, Garofalo J, Krishnan JA, **Cavallari LH**, Nutescu EA. Impact of a pharmacist-guided pharmacogenetics service on prediction of warfarin stable dose. *Pharmacotherapy* 2014;34(10):e220 (#415). Poster presentation at the 2014 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX. **\*\*Best Student Poster Finalist**. October 13, 2014



99. Nutescu E, Duarte J, Cheng W, Sarangpur S, Gor D, Drozda K, Galanter W, Stamos T, Peace D, Garofalo J, Krishnan J, **Cavallari L**. Novel genotype guided personalized warfarin service improves outcomes in an ethnically diverse population. *Circulation* 2014;103:A16119. Poster presentation at the American Heart Association's Scientific Sessions. Chicago, IL. November 17, 2014.
100. Drozda K, Lee YM, Patel SR, Lee J, Pugach O, Duarte JD, Nutescu EA, **Cavallari L**. Genetic associations with warfarin response in patients receiving genotype-guided dosing. *Clin Pharmacol Ther* 2015;97(S1):S26 (#PI-018). Poster presentation at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting. New Orleans, LA. March 5, 2015.
101. Nwanze N, Hernandez W, Tuck M, O'Brien T, Kittles R, Duarte J, Bourgeois S, **Cavallari L**, Perera M. Genome-wide association study to identify susceptibility loci associated with hemorrhagic complications among African American patients on stable warfarin dose. *Clin Pharmacol Ther* 2015;97(S1):S66 (#PII-026). Poster presentation at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting. New Orleans, LA. March 6, 2015.
102. **Cavallari LH**, Magvanjav O, Anderson RD, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Eley AR, Cooper-Dehoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Fewer cardiovascular events after percutaneous coronary intervention with genotype-guided antiplatelet therapy: results from the UF Health Personalized Medicine Program. Moderated poster presentation at the Late-Breaking/Encore Abstract Poster Walk, American Society of Clinical Pharmacology and Therapeutics 2015 Annual Meeting. March 5, 2015. Full abstract published in the Final Meeting Program. Pp.170-171. #LBPW-4.
103. Hernandez W, Gamazon ER, Konkashbaev A, Kittles RA, **Cavallari LH**, Perera MA. Genome-wide association study identifies novel susceptibility loci for venous thromboembolism in African Americans. *Clin Pharmacol Ther* 2015;97(S1):S66 (#PII-026). Poster presentation at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting. New Orleans, LA. March 6, 2015.
104. Weitzel KW, Darwiche H, Eley AR, **Cavallari LH**, Koroly MJ, Johnson JA, Nelson DR. Development of a pharmacogenomics curriculum for secondary teachers: collaboration supports translational workforce development. *Clin Transl Sci* 2015;8(3):243. Presented at the Association of Clinical and Translational Science 2015 Annual Meeting, Washington DC, April 17, 2015.
105. Kim K, Gor D, Walton SM, Galanter WL, Duarte J, Krishnan JA, Bauman JL, **Cavallari LH**, Nutescu EA. Novel pharmacist-guided pharmacogenetic service lowers warfarin-related hospitalizations. *Value in Health* 2015;18(3): A130. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 20<sup>th</sup> Annual International Meeting. May 19, 2015. Philadelphia, PA.
106. Lee WJ, Chumnumwat S, Duarte J, Gratie D, Galanter WL, Walton SM, Krishnan JA, Bauman JL, **Cavallari LH**, Nutescu EA. Factors that negatively influence the prediction of warfarin stable dose when employing a genotype-guided approach. *Value in Health*

- 2015;18(3):A136. Poster presentation at the ISPOR 20<sup>th</sup> Annual International Meeting. May 19, 2015. Philadelphia, PA.
107. Manzoor B, Duarte J, Lee J, Galanter W, Walton S, Galanter N, Krishnan J, Bauman J, **Cavallari L**, Nutescu E. The impact of race on the association between a novel genotype-guided personalized warfarin service and clinical outcomes in an ethnically diverse population. *Value in Health* 2015;18(3):A131. Poster presentation at the ISPOR 20<sup>th</sup> Annual International Meeting. May 19, 2015. Philadelphia, PA.
108. Hamadeh I, Shahin MH, Lima SM, Oliveira F, Wilson L, Khalifa SI, Langaee TY, **Cavallari LH**, Johnson JA. Impact of *GGCX*, *STX1* and *FPGS* polymorphisms on warfarin dose requirement in Caucasians and Egyptians. *Pharmacotherapy* 2015;35(11):e207 (#134). Poster presentation at the 2015 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. October 18, 2015. San Francisco, CA.
109. Weitzel K, **Cavallari LH**, Eley AR, Owusu Obeng A, Staley B, Ashton J, Vo T, Kong B, Ramos M, Higgins T, Cooper-DeHoff, R, Johnson JA. Development and implementation of pharmacist-led clinical pharmacogenetics services within a personalized medicine program. *Pharmacotherapy* 2015;35(11):e225 (#208). Poster presentation at the 2015 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. October 18, 2015. San Francisco, CA.
110. Ohler K, Raithel D, Pham J, **Cavallari LH**, Kraus D. Neonatal indomethacin for prevention of intraventricular hemorrhage: a study of plasma concentrations, pharmacogenomic factors, and outcomes. *Pharmacotherapy* 2015;35(11):e203 (#119). 2015 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. October 18, 2015. San Francisco, CA.
111. **Cavallari LH**, Magvanjav O, Anderson RD, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Eley AR, Cooper-Dehoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Fewer cardiovascular events after percutaneous coronary intervention with genotype-guided antiplatelet therapy: results from the UF Health Personalized Medicine Program. Encore poster presentation (#130E) at the 2015 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. October 19, 2015. San Francisco, CA.
112. **Cavallari LH**, Magvanjav O, Anderson RD, Gong Y, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Eley AR, Allan RW, Starostik P, Cooper-DeHoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical implementation of *CYP2C19* genotype guided antiplatelet therapy reduces cardiovascular events after PCI. *Circulation* 2015;132(A11802). Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL. Available through [http://circ.ahajournals.org/content/132/Suppl\\_3/A11802.abstract?sid=cd6bc466-3451-41a8-8339-503e71988d82](http://circ.ahajournals.org/content/132/Suppl_3/A11802.abstract?sid=cd6bc466-3451-41a8-8339-503e71988d82)
113. De T, Nwanze N, Hernandez W, Smithberger E, Tuck M, O'Brien T, Kittles R, Duarte JD, Bourgeois S, **Cavallari L**, Perera M. Genome-wide association study to identify the genetic determinants of warfarin induced hemorrhagic complications in African Americans. *Clin Pharmacol Ther* 2016;99(S1):S73 (#PWII-2, PT-03). Poster walk presentation at the American Society for Clinical Pharmacology and Therapeutics 2016 Annual Meeting. San Diego, CA. March 9, 2016.

114. Hamadeh IS, Klinker KP, Borgert SJ, Richards AM, Li W, Ramos M, Mangal N, Hiemenz JW, Schmidt S, Peloquin CA, **Cavallari LH**, Johnson JA. Investigating the impact of CYP2C19 ultrarapid metabolizer phenotype on voriconazole exposure in patients with invasive fungal infections. Poster presentation at the Late-Breaking/Encore Abstract Poster Walk, American Society of Clinical Pharmacology and Therapeutics 2016 Annual Meeting. San Diego, CA. March 11, 2016. Full abstract published in the Final Meeting Program.
115. Lima SM, Theofilogiannakos EK, Boudoulas KD, Shahin MH, Hamadeh IS, Langaee TY, **Cavallari LH**, Pitsis AA, Boudoulas H. Genetic determination of collagen synthesis and degradation in patients with floppy mitral valve/mitral valve prolapse. *J Am Coll Cardiol*. 2016;67;13(S5):2221 (#1170-046). Poster presentation at the American College of Cardiology 65<sup>th</sup> Annual Scientific Session & Expo. Chicago, IL. April 4, 2016.
116. Bargal S, Kight J, de Oliveira F, Shahin M, Langaee T, Gong Y, Hamadeh I, Cooper-DeHoff R, **Cavallari L**. Implications of polymorphisms in *BCKDK* and *GATA-4* genetic regions on stable warfarin dose in African Americans. *Pharmacotherapy* 2016;36(12):e267 (#250). Poster and platform presentation at the 2016 Annual Meeting of the American College of Clinical Pharmacy. Hollywood, FL. October 23-26, 2016. **\*\*Finalist for Best Student Poster.**
117. Nys C, Weitzel K, Elsey A, Lovato B, Schmidt SO, Johnson J, **Cavallari L**. Determining the potential value of preemptive multi-variant genotyping in primary care clinics. Research in progress poster presentation at the 2016 Annual Meeting of the American College of Clinical Pharmacy (abstract #456). Hollywood, FL. October 23-26, 2016.
118. Lovato B, Weitzel K, Elsey A, McDonough CW, Gong Y, Fillingim RB, Schmidt SO, Johnson JA, **Cavallari L**. Factors influencing beliefs about pharmacogenetics testing in patients with chronic pain. Research in progress poster presentation at the 2016 Annual Meeting of the American College of Clinical Pharmacy (abstract #455). Hollywood, FL. October 23-26, 2016.
119. Smith DM, Elsey A, Johnson J, **Cavallari LH**, Weitzel K. Feasibility of implementing a personalized approach to chronic pain management using cytochrome P450 2D6 genotype in a primary care clinic. Research in progress poster presentation at the 2016 Annual Meeting of the American College of Clinical Pharmacy (abstract #389). Hollywood, FL. October 23-26, 2016.
120. Mosley S, Wake D, Liu X, Weitzel K, Elsey A, Winterstein A, Johnson J, **Cavallari L**. Potential value of preemptive panel-based pharmacogenetics testing in patients undergoing cardiac catheterization. Research in progress poster presentation at the 2016 Annual Meeting of the American College of Clinical Pharmacy (abstract #390). Hollywood, FL. October 23-26, 2016.
121. Hamadeh I, Takahashi H, **Cavallari L**. *R*-warfarin clearance and its effect on warfarin dose requirements in African Americans. *Pharmacotherapy* 2016;36(12):e267 (#249). Poster presentation at the 2016 Annual Meeting of the American College of Clinical Pharmacy. Hollywood, FL. October 23-26, 2016.

122. Deng J, Arwood M, Duarte J, **Cavallari L**, Schmidt S. Development of a universal pharmacogenetics-guided warfarin dosing nomogram. Poster presentation at the Seventh American Conference on Pharmacometrics meeting. Bellevue, WA. October 23-26, 2016.
123. Duarte JD, Arwood MJ, Liko I, Mansour I, Nair V, Kansal M, Stamos T, **Cavallari LH**, Desai AA. Beta-blocker dose stratifies both mortality risk and circulating procollagen levels in African Americans with heart failure. *Circulation*. 2016;134:A11877. Poster presentation at the American Heart Association's Scientific Sessions. New Orleans, LA. November 15, 2016.
124. **Cavallari LH**, Denny JC, Lee CR, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective Clinical Implementation of *CYP2C19*-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. *Circulation* 2016;134:e711-712 (abstract #21050). Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association's Scientific Sessions. New Orleans, LA. November 15, 2016.
125. Sperber N, Orlando L, Carpenter J, **Cavallari L**, Denny J, Eelsey A, Fitzhenry F, Guan Y, Horowitz C, Johnson J, Madden E, Pollin T, Pratt V, Rakhra-Burris T, Rosenman M, Voils C, Weitzel K, Wu R, Damschroder L. Challenges and Strategies for Implementing Genomic Services in Diverse Settings: Experiences from the Implementing Genomics in Practice (IGNITE) Network. Presentation at the 9th Annual Conference on the Science of Dissemination and Implementation. Washington, DC. December 14-15, 2016.
126. Nys C, Weitzel K, Schmidt SO, Eelsey A, Johnson JA, **Cavallari LH**. Determining the potential value of preemptive multi-variant genotyping in primary care clinics. Poster presentation at the University of Florida Precision Medicine Conference. Orlando, FL. March 9, 2017. #1106.
127. Fletcher-Hoppe C, **Cavallari L**, Denny J, Dexter P, Ginsburg G, Horowitz C, Johnson J, Levy K, Levy M, Orlando L, Owusu-Obeng A, Overby C, Peterson J, Pollin T, Pratt V, Junkins H, Madden E, Manolio T, Weitzel K. Supporting practice through application, resources, and knowledge (SPARK): Solutions to genomic medicine implementation developed by the IGNITE Network. Poster presentation at the University of Florida Precision Medicine Conference. Orlando, FL. March 9, 2017. #1111.
128. Mosley S, Wake D, Liu X, Weitzel K, Eelsey A, Winterstein A, Starostik P, Clare-Salzler M, Nelson D, Johnson J, **Cavallari L**. Potential value of preemptive panel-based pharmacogenetic testing in patients undergoing cardiac catheterization. Poster presentation at the University of Florida Precision Medicine Conference. Orlando, FL. March 9, 2017. #1120.
129. Smith DM, Kong B, Vo T, Higgins T, Staley B, Eelsey A, **Cavallari L**, Johnson JA, Weitzel K. Characteristics of thiopurine S-methyltransferase (*TPMT*) testing at University of Florida Health. Poster presentation at the University of Florida Precision Medicine Conference. Orlando, FL. March 9, 2017. #1129.

130. Arwood MJ, Deng J, Drozda K, Nutescu EA, Schmidt S, Duarte JD, **Cavallari LH**. Clinical implementation of warfarin pharmacogenetics in a real-world setting: a proposal for a new pharmacogenetic dosing approach for diverse patient populations. *Clin Pharmacol Ther* 2017;101(S1):S5 (#PT-002). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2017 Annual Meeting. Washington, DC. March 15-18, 2017. **\*\*Selected as a Top Trainee Abstract.**
131. Basu S, Samant T, Trescor A, Palmer M, **Cavallari L**, Lesko L, Schmidt S. Development and application of a pharmacogenetics guided PBPK model for prediction of the drug-drug interaction (CCI) of oxycodone and CYP perpetrators. *Clin Pharmacol Ther* 2017;101(S1):S56 (#PII-009). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2017 Annual Meeting. Washington, DC. March 15-18, 2017.
132. Hernandez W, Gamazon ER, Konkashbaev AI, **Cavallari LH**, Stranger B, Perera MA, International Warfarin Pharmacogenetics Consortium. Genome-wide copy number variation and warfarin dose response in African Americans. *Clin Pharmacol Ther* 2017;101(S1):S96 (#PWIV-005). Moderator poster at the American Society of Clinical Pharmacology and Therapeutics 2017 Annual Meeting. Washington, DC. March 15-18, 2017.
133. Arwood MJ, McDonough CW, **Cavallari LH**, Elsey AR, Frye RF, Gong Y, Langae T, Johnson JA, Weitzel KW. Equipping health professional students to apply pharmacogenomic data to clinical decision making in real-world scenarios: Comparison of an active engagement versus didactic teaching approach. Poster presentation at the Translational Science 2017 Annual Meeting. Washington, DC. April 20 2017.
134. Mosley S, Hicks JK, Donovan KA, George TJ, Gopalan P, Clare-Salzler M, Schmit J, Silver N, Starostik P, Starr J, McLeod HL, **Cavallari L**. Pharmacogenetic (PGx) service incorporating *CYP2D6* genotype to guide opioid prescribing for cancer pain at two academic cancer centers in Florida. *Pharmacotherapy* 2017;37(12):e226 (#366). Poster presentation at the 2017 Annual Meeting of the American College of Clinical Pharmacy. Phoenix, AZ. October 7-10, 2017.
135. El Rouby N, Alrwisan A, Johnson JA, Winterstein AG, **Cavallari L**. Utilization of drugs with evidence for pharmacogenomic testing following percutaneous coronary intervention. Poster presentation at the 67<sup>th</sup> Annual Meeting of the American Society of Human Genetics. Orlando, FL. October 19, 2017.
136. Dumeny L, Chantra M, Langae T, Duong B, Zambrano D, Han F, Humma J, DaCosta J, Lovato T, Mei C, Bleiweis M, Johnson J, **Cavallari L**. B1-adrenoceptor polymorphisms associated with post-operative arrhythmias in children after congenital cardiac surgery. Poster presentation at the Pharmacogenomics Research Network Poster Session in conjunction with the American Society of Human Genetics meeting. Orlando, FL. October 19, 2017. **\*\*One of four abstracts selected for a PGRN Trainee Award**
137. Smith DM, Weitzel KW, Elsey AR, Wake DT, Blotner A, Budd J, Chang K, Elwood E, Fillingim R, Griff J, Hagan H, Hagen M, Harrell J, Hollifield W, Konopack J, Mercado E, Nagoshi Y, Newsom K, Orlando F, Smith SM, Westwoor G, Wright A, Yale E, Starostik P, Clare-Salzler C, Schmidt S, Johnson JA, **Cavallari LH**. Feasibility of clinically implementing

*CYP2D6* genotype-guided opioid therapy. Poster presentation at the Pharmacogenomics Research Network Poster Session in conjunction with the American Society of Human Genetics meeting. Orlando, FL. October 19, 2017.

138. Limdi NA, Holmes A, Skaar T, **Cavallari L**, Beitelshees AL, Dillon C, Pisu M, Duarte J, Empey PE, Gong Y, Hillegass WB, Johnson J, Lee CR, Garbett S, Zhou Z, Graves J, Peterson JF. Real world cost-effectiveness of *CYP2C19*-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention. Poster presentation at the 39<sup>th</sup> Annual North American Meeting of the Society for Medical Decision Making. Pittsburgh, PA. October 22-25, 2017.
139. Lovince J, Mosley S, Gopalan P, George T, **Cavallari L**. Assessing the feasibility of clinical application of *CYP2D6* genotype-guided opioid prescribing for patients with cancer-related pain. Poster presentation at the 2017 Midyear Meeting of the American Society of Health-System Pharmacists (abstract # 384941). Orlando, FL. December 3-7, 2017.
140. Mosley S, Frye R, Langae T, Schmidt SOF, Schmidt S, Gong Y, Binkley P, Johnson JA, **Cavallari LH**. Determination of *CYP2D6* phenotyping for metoprolol using the genotype-derived activity score. Poster presentation for American College of Clinical Pharmacy Updates in Therapeutics 2018 Meeting (F-42). Jacksonville, FL. February 16-18, 2018.
141. Smith DM, Weitzel KW, Eley AR, Wake DT, Gong Y, Duong BQ, Newsom K, Smith SM, Starostik P, Clare-Salzler MJ, Schmidt SO, Johnson JA, Fillingim R, **Cavallari LH**. Outpatient *CYP2D6* genotype-supported opioid therapy: a prospective trial. *Clin Pharmacol Ther* 2018;103 (S1):S8. (PT-012). Poster walk presentation at the American Society of Clinical Pharmacology and Therapeutics 2018 Annual Meeting. Orlando, FL. March 21-24, 2018. **\*\*Selected for a Presidential Trainee Award.**
142. Dumeny L, Chantra M, Langae TY, Duong BQ, Zambrano DH, Han FY, Humma JF, Dacosta JP, Lovato TB, Mei CH, Johnson JA, Bleiweis MS, **Cavallari LH**. Beta1-adrenergic receptor genotype and susceptibility to junctional ectopic tachycardia after congenital heart surgery. *Clin Pharmacol Ther* 2018;103 (S1):S31. (PI-063). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2018 Annual Meeting. Orlando, FL. March 21-24, 2018.
143. El Rouby N, Mosley S, Wake D, Liu X, Weitzel KW, Eley AR, Riva A, Langae T, Winterstein AG, Johnson JA, **Cavallari LH**. Prevalence of actionable genotypes and drug exposure among patients undergoing cardiac catheterization in the University of Florida Personalized Medicine Program. *Clin Pharmacol Ther* 2018;103 (S1):S31. (PI-064). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2018 Annual Meeting. Orlando, FL. March 21-24, 2018.
144. Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, Coons JC, Duarte JD, Franchi F, Jeng LJ, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, **Cavallari LH**, Lee CR. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther* 2018;103 (S1):S31-S32. (PI-066). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2018 Annual Meeting. Orlando, FL. March 21-24, 2018.

145. Fathy S, Shahin MH, Langae T, Khalil BM, Saleh A, Sabry NA, El-Wakeel LL, **Cavallari LH**, Schaalán MF. Identifying factors associated with variability in response to clopidogrel therapy in Egyptian patients with acute coronary syndrome. *Clin Pharmacol Ther* 2018;103(S1):S32. (PI-068). Poster presentation at the American Society of Clinical Pharmacology and Therapeutics 2018 Annual Meeting. Orlando, FL. March 21-24, 2018.
146. Duong BQ, Arwood MA, Hicks JK, Beitelshes AL, Eley AR, Franchi F, Limdi NA, Mills AE, Owusu-Obeng A, Petry N, Tuteja S, **Cavallari LH**, Weitzel KM, on behalf of the IGNITE Network. Development of an implementation guide to support clinical adoption of genomic medicine: Experiences of the Implementing Genomics in Practice (IGNITE) Network. Poster presentation at the American College of Medical Genetics 2018 Annual Meeting. Charlotte, NC. April 13, 2018.
147. Dumeny L, Hsiao C, **Cavallari L**, Mulligan C, McCormack W. TL1 team approach to social and genetic determinants of nocturnal blood pressure. Oral and Poster presentation at the Translational Science 2018 meeting. Washington DC. April 19-21, 2018.
148. Brown J, **Cavallari L**, Nelson D, Schmidt S, Esteban VV, Winterstein AG, Johnson JA. Joint approaches in pharmacoepidemiology, precision medicine and pharmacometrics to explain, predict and optimize drug therapy. Poster presentation at the American Association of College of Pharmacy 2018 meeting. Boston, MA. July 21-25, 2018.
149. Smith DM, Cicali EJ, Duong BQ, Kovar L, **Cavallari LH**, Johnson JA. Assessing the evidence behind CYP2D6 inhibitor classifications; a systematic review. *J Am Coll Clin Pharm.* 2018;1(2):122-353. (#47411). Poster presentation at the 2018 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. Seattle, WA. October 20-23, 2018.
150. Arwood MJ, Dietrich EA, Duong BQ, Smith DM, Rosenberg EI, Huber KN, Nagoshi YL, Wright A, Budd JT, Eley AR, **Cavallari LH**, Weitzel KW, Johnson JA, Gums JG. Implementation of a pharmacist-led pharmacogenetics consult clinic in a primary care setting. Platform presentation at the 2018 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. Seattle, WA. October 21-22, 2018.
151. Shahin MH, Kovar LG, Smith DM, Eley AR, Weitzel KW, Anderson RD, Cooper-DeHoff RM, Nelson DR, Johnson JA, **Cavallari L**. Impact of different P2Y<sub>12</sub> inhibitors on cardiovascular outcomes in diabetic versus non-diabetic patients: insights from real-world data. *Circulation* 2018;138:A12787. Poster presentation at the American Heart Association's Scientific Sessions 2018, Chicago, IL. November 11, 2018.
152. Vahabi N, Arwood MJ, **Cavallari LH**, Machado RF, Duarte JD. Transcriptome-wide analysis of pulmonary hypertension in heart failure with preserved ejection fraction patients implicates mitochondrial and proliferative pathways. *Circulation* 2018;138(s1):A13456. ([https://www.ahajournals.org/doi/10.1161/circ.138.suppl\\_1.13456](https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.13456)). Poster presentation at the American Heart Association's Scientific Sessions 2018, Chicago, IL. November 11, 2018.
153. Dumeny L, Hsiao C, Bress AP, **Cavallari LH**, Johnson DA, Mulligan CJ, Shimbo D. Validation of *SGCD* (rs2116737) genotype-discrimination interaction as a determinant of blood pressure variation in the Jackson Heart Study. Poster presentation at the American

---

Heart Association Epidemiology and Prevention | Lifestyle and Cardiometabolic Health  
2019 Scientific Sessions. Houston, TX. March 5-8, 2019.

154. Hsiao C, Dumeny L, Bress AP, Shimbo D, **Cavallari LH**, Johnson DA, Mulligan CJ. TL1 team approach to validating genotype-discrimination interaction variants in nocturnal blood pressure in the Jackson Heart Study. Poster presentation at the Association for Clinical and Translational Science Meeting 2019. Washington D.C. March 5-8, 2019.
155. **Cavallari LH**, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Owusu Obeng A, Beitelshes AL, Bell GC, Blake K, Crona DJ, Dressler L, Empey PE, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Peterson JF, Johnson JA, Skaar TC. Multi-site Investigation of Strategies for the Clinical Implementation of *CYP2D6* Genotype-Guided Therapies. *Clin Pharmacol Ther* 2019;105(S1):S88 (PIII-023). Poster presentation at American Society of Clinical Pharmacology and Therapeutics 2019 Annual Meeting. Washington DC. March 13-16, 2019.
156. El Rouby N, Langae T, Elsey A, Riva A, **Cavallari LH**, Johnson JA. Estimating the clinical value of a customized cardiovascular pharmacogenetics panel. *Clin Pharmacol Ther* 2019;105(S1):S16, 93 (PGRN-004, PIII-040). Poster presentation at American Society of Clinical Pharmacology and Therapeutics 2019 Annual Meeting. Washington DC. March 13-16, 2019.
157. El Rouby N, Marcatto L, Claudio K, Tavares L, Steiner H, Botton MR, Lubitz SA, Scott SA, Karnes J, **Cavallari LH**, Santos PCD, Duconge J. Multi-site investigation of pharmacogenetic determinants of warfarin dose variability in Latinos. *Clin Pharmacol Ther* 2019;105(S1):S24 (PT-004). Platform presentation at American Society of Clinical Pharmacology and Therapeutics 2019 Annual Meeting. Washington DC. March 13-16, 2019.  
**\*\*Selected for a Presidential Trainee Award.**
158. Sarhan N, El Rouby NM, Solayman MH, Shahin MH, Langae T, Khorshid H, El-Wakeel L, Schaalman MF, Sabri NA, **Cavallari LH**. Effect of genetic polymorphisms on clinical response to mineralocorticoid receptor antagonist therapy in patients with heart failure. *Clin Pharmacol Ther* 2019;105(S1):S21 (PGRN-021). Poster presentation at American Society of Clinical Pharmacology and Therapeutics 2019 Annual Meeting. Washington DC. March 13-16, 2019.
159. Thomas CD, Mosley SA, El Rouby N, Kim S, Lingineni K, Langae T, Gong Y, Johnson JA, Schmidt SO, Schmidt S, Frye RF, **Cavallari LH**. Determination of *CYP2D6* phenotyping for metoprolol using the *CYP2D6* genotype-derived activity score: results from a prospective, clinical trial. *Clin Pharmacol Ther* 2019;105(S1):S40 (LB-028). Late breaking abstract presentation at the American Society of Clinical Pharmacology and Therapeutics 2019 Annual Meeting. Washington DC. March 13-16, 2019.
160. Hicks JK, Ong HH, Schildcrout JS, Shi Y, Tang LA, El Rouby N, Aquilante CL, Beitelshes AL, Blake KV, Empey PE, Limdi NA, Lipori GP, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley L, Williams H, Winterstein AG, Van Driest S, Ramsey L, **Cavallari LH**, Peterson JF. Evaluation of CPIC level A drug prescribing in IGNITE-affiliated health systems: opportunity for pharmacogenomics implementation among adult patients. Poster presentation at the Clinical Pharmacogenetics Implementation Consortium (CPIC) Open meeting. Memphis TN. June 6-7, 2019.



161. Ramsey LB, Ong HH, Tang LA, Schildcrout JS, Shi Y, Hicks JK, Blake KV, Williams H, Rosenman MB, Teal E, Skaar TC, Beitelshes AL, Aquilante CL, Tuteja S, Empey PE, Horvat CM, Limdi NA, Owusu Obeng A, Ellis SB, Salyakina D, McCafferty-Fernandez J, Gruber, J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, **Cavallari LH**, El Rouby N, Lipori GP, Winterstein AG, Peterson JF, Van Driest SL. Opportunity for pharmacogenetic prescribing in pediatric hospitals in the IGNITE network. Poster presentation at the Clinical Pharmacogenetics Implementation Consortium (CPIC) Open meeting. Memphis TN. June 6-7, 2019.
162. Cicali EJ, Cook K, Smith DM, Elchynski A, Johnson JA, Cavallari LH, Wiisanen K. Development of an algorithm to calculate clinical CYP2D6 phenoconversion in practice. Poster presentation at the 2019 American College of Clinical Pharmacy Annual Meeting. New York, NY. October 26-29, 2019.
163. Hicks JK, Ong HH, Schildcrout JS, Shi Y, Tang LA, El Rouby N, Aquilante CL, Beitelshes AL, Blake KV, Empey PE, Limdi NA, Lipori GP, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley L, Williams H, Winterstein AG, Van Driest S, Ramsey L, **Cavallari LH**, Peterson JF. Evaluation of CPIC level A drug prescribing in IGNITE-affiliated health systems: opportunity for pharmacogenomics implementation among adult patients. 2019 American College of Clinical Pharmacy Annual Meeting. New York, New York. October 28, 2019.
164. Thomas CD, Elsey AR, Starostik P, Gong Y, Deen JT, Pulido LF, Prieto HA, Fillingim R, Gray CF, Parvataneni HK, Johnson JA, **Cavallari LH**. A pilot clinical trial of a CYP2D6 genotype-guided pain management strategy in patients undergoing total joint arthroplasty. Poster presentation at the Pharmacogenomics Research Network-American Society of Human Genetics Poster Session. Houston, TX. October 15-19, 2019.
165. Elchynski A, Cicali E, Chang K, Nys C, Elsey A, Johnson J, Wiisanen K, Schmidt S, **Cavallari L**. Determining the potential value of panel-based pharmacogenetic testing in a chronic pain population. *Clin Pharmacol Ther* 2020;107(S1):S14 (PGRN-005, PII-078).
166. Thomas C, Elsey A, Starostik P, Gong Y, Deen J, Pulido L, Prieto H, Fillingim R, Gray C, Parvataneni H, Johnson J, **Cavallari L**. Precise pain control: feasibility and efficacy of a preemptive CYP2D6-genotype guided post-operative pain management paradigm. *Clin Pharmacol Ther* 2020;107(S1):S20 (PGRN-029, PT-013). **\*\*Selected for a Presidential Trainee Award.**
167. Dumeny L, **Cavallari L**, Duarte J, Vardeny O, Edelmann F, Pieske B. NR3C2 genotype is associated with spironolactone response in heart failure with preserved ejection fraction – data from the Aldo-DHF trial. *Clin Pharmacol Ther* 2020;107(S1):S14 (PGRN-004, PIII-027).
168. Cicali E, Cook K, Arwood M, Staley B, Thomas C, Dalton R, Elsey A, **Cavallari L**, Johnson J, Cooper-DeHoff R, Wiisanen K. Development of standardized clinical resources to support implementation of a preemptive pharmacogenomic testing panel. *Clin Pharmacol Ther* 2020;107(S1):S57 (PII-079).
169. Mosley S, El Rouby N, Kim S, Lingineni K, Gong Y, Feng K, Kim H, Kinjo M, Langae T, Schmidt S, Johnson J, Frye R, Binkley P, Schmidt S, **Cavallari L**. Zhao L, Estores D, Li Z.

Randomized, prospective, clinical trial comparing metoprolol succinate extended-release (ER) formulation. *Clin Pharmacol Ther* 2020;107(S1):S99(PIII-080).

170. Sheikh S, Fillingim RB, **Cavallari LH**, Patel M, Gong Y, Chen Y, Langae T, Wang D. Comparing Risk for Prescription Opioid Misuse and Abuse in Patients With High- Versus Low- Pain Interference From Chronic Musculoskeletal Pain: Preliminary results. Accepted for poster presentation at the IASP 2020 World Congress on Pain, Amsterdam, Netherlands. August 4-8, 2020.

## INVITED PRESENTATIONS

“Late Breaking Clinical Trials in Cardiovascular Pharmacotherapy: PRAISE II.” Cardiology Focus Session at the 2000 Meeting of the American College of Clinical Pharmacy. Los Angeles, CA. November 2000.

“Current and Future Applications of Pharmacogenetics in Cardiology.” Illinois/ Missouri Health-System Pharmacy Seminar. St. Louis, MO. March 2001.

“Outpatient Cardiology.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2001 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Salt Lake City, UT. April 2001.

“Critical Care.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2001 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Salt Lake City, UT. April 2001.

“Management of Cardiovascular Diseases in the Age of Genomics.” Pharmacogenomics Curricular Track 2: Therapeutic Opportunities in the Age of Genomics, 2001 American College of Clinical Pharmacy Annual Meeting. Tampa, FL. October 2001.

“The Impact of Genetics on Drug Pharmacokinetics and Pharmacodynamics.” Pharmacokinetics/ Pharmacodynamics and Geriatrics Focus Session at the 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.

“Outpatient Cardiology.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.

“Critical Care.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.

“Predicting Drug Response with Pharmacogenomics.” Keynote address for the Ohio College of Clinical Pharmacy 2002 Spring Meeting. Plains, OH. May 2002.

“Management of Cardiovascular Diseases in the Age of Genomics.” Cardiology Grand Rounds. University of Florida at Shands Hospital. Jacksonville, FL. June 2002.

“Pharmacogenomics 101.” 2002 South Carolina Society of Health-System Pharmacist Fall Symposium. Charleston, SC. October 2002.

“Predicting Drug Response with Pharmacogenomics.” Maryland Society of Health-System Pharmacists 37<sup>th</sup> Annual Seminar Pharmacotherapy Update. Cambridge, MD. October 2002.

“So you want to present an abstract at a national meeting? Preparing for a poster presentation” Career Development Curricular Track at the 2002 Annual Meeting of the American College of Clinical Pharmacy. Albuquerque, NM. October 2002.

“Genetic Influences of Responses to Cardiovascular Drugs.” Program Title: Pharmacogenomics: The Future is Now! Current Applications in Clinical Practice. 2002 Midyear Clinical Meeting of the American Society of Health-System Pharmacists. Atlanta, GA. December 2002.

“Outpatient Cardiology.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2003 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Palm Springs, CA. April 2003.

“Critical Care.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2003 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Palm Springs, CA. April 2003.

“Optimizing Pharmacotherapy with Pharmacogenomics.” 2004 Annual Meeting of the Vermont Society of Health-System Pharmacists. Burlington, VT. March 2004.

“The Impact of Pharmacogenetics on Drug Response and Applications to Disease Management.” 40th Annual Meeting of the Drug Information Association. Washington, DC. June 15, 2004.

“Personalized Management of Cardiovascular Diseases.” Personalized Medicine e-Symposium ([www.pm.e-symposium.com](http://www.pm.e-symposium.com)). Hosted by the International Society of Pharmacogenomics. June 2006.

“Clinical Applications of Genetic Testing.” Meet the Experts Roundtable Discussion. 2006 Annual Meeting of the American College of Clinical Pharmacy. St. Louis, MO. October 2006.

“Personalized Management of Cardiovascular Diseases.” Pharmacogenomics, Pharmacology, and Toxicology Forum, Department of Pathology at the Medical College of Wisconsin. Milwaukee, WI. March 2008.

“Patient Specific Factors Affecting Response to Aldosterone Antagonists.” Department of Pharmacy Practice/Center for Pharmacogenomics Seminar Series. University of Florida, Gainesville, FL. March 2009.

“Pharmacogenomics Applications in the Real World – Warfarin and Cardiovascular Pharmacogenomics.” 2010 Spring Practice and Research Forum, American College of Clinical Pharmacy. Charlotte, NC. April 24, 2010.

“Warfarin Pharmacogenomics in African Americans.” George Washington University. Washington, DC. May 5, 2010.

“Optimizing Pharmacotherapy with Pharmacogenomics.” Illinois Council of Health-System Pharmacists 2010 Annual Meeting. Oakbrook Terrace, IL. August 27, 2010.

“Cardiology I.” Webinar. Pharmacogenomics Education™ Program (PharmGenEd): Bridging the Gap between Science and Practice. September 21, 2010.

“Cardiology II.” Webinar. Pharmacogenomics Education™ Program (PharmGenEd): Bridging the Gap between Science and Practice. September 23, 2010.

“Beyond the Job Description: Ask the Experts Panel Discussion.” Career Paths 101: Deciding, Obtaining, and Succeeding. Resident Advisory Committee Session, 2010 Annual Meeting of the American College of Clinical Pharmacy. Austin, TX. October 16, 2010.

“Late Breakers I: Cardiovascular Therapeutics.” 2010 Annual Meeting of the American College of Clinical Pharmacy. Austin, TX. October 18, 2010.

“Medication Effectiveness Based on Genotype.” North Suburban Pharmacists Meeting. Northbrook, IL. October 19, 2010.

“Warfarin Pharmacogenomics: A Focus on African Americans.” Rho Chi Pharmacy Honor Society Speaker Series, Inaugural Event. St. Louis College of Pharmacy. St. Louis, MO. November 18, 2010.

“Implementing Genomics into Drug Therapy Decisions.” 10<sup>th</sup> Annual Geriatric Symposium. Columbia, SC. February 5, 2011.

“Pharmacogenetics: Genetic Contributions to Drug Response.” Dupage Pharmacist Association. Oak Park, IL. May 18, 2011.

“Clinical Implications and Educational Applications of Warfarin Pharmacogenomics.” Pharmacogenomics SIG session, Clinical and Educational Aspects of Pharmacogenomics, American Association of Colleges of Pharmacy Annual Meeting. San Antonio, TX. July 11, 2011.

“Warfarin Pharmacogenomics in African Americans.” Graduate Student Research Seminar. Nova Southeastern University. Fort Lauderdale, FL. December 2, 2011.

“Warfarin Pharmacogenetics in Minority Populations.” Rosalind Franklin University. North Chicago, IL. December 13, 2011.

“Personalized Medicine.” University of Illinois at Chicago Campus Insights Program. Presentation to the University of Illinois Board of Trustees, President, Chancellor, UIC Deans and Vice Chancellors, External Constituents, and members of the community. Attendees included Board President, Chris Kennedy; Illinois State Representative, Daniel Biss; and Secretary of State, Jesse White. University of Illinois at Chicago. January 18, 2012.

“Pharmacogenomics in Cardiovascular Disease: Ready for Prime-time?” Presentation for the 33<sup>rd</sup> Annual Madison Clinical Conference on Prevention and Management of Cardiovascular Diseases. Madison, WI. March 21, 2012.

“How to Use Pharmacogenetics in Practice.” Workshop for the 33<sup>rd</sup> Annual Madison Clinical Conference on Prevention and Management of Cardiovascular Diseases. Madison, WI. March 21, 2012.

“Implementation of Clopidogrel Pharmacogenetics at the University of Illinois Hospital and Health Sciences System.” One-hour CME and CPE. University of Illinois at Chicago College of pharmacy. June 27, 2012.

“Implementation of Warfarin Pharmacogenetics at the University of Illinois Hospital and Health Sciences System.” One-hour CPE and CME provided. University of Illinois at Chicago, College of Pharmacy. July 25, 2012.

“Closing the Gaps in the World of Pharmacogenomics.” 8<sup>th</sup> Annual New England Pharmacists Convention. Mashantucket, CT. September 28, 2012.

“Tenure Track Faculty Roundtable.” Clinical Pharmacy Career Path Roundtable Session. American College of Clinical Pharmacy 2012 Annual Meeting. Hollywood, FL. October 21, 2012.

“Research and Clinical Implementation of Warfarin Pharmacogenomics in Underrepresented Populations.” Department of Experimental and Clinical Pharmacology Research Seminar, University of Minnesota College of Pharmacy, Minneapolis, MN. January 23, 2013.

“Implementation of Warfarin Genetics at UI-Health.” Webinar presented to faculty and staff at St. Jude Children’s Research Hospital, Memphis, TN. February 20, 2013.

“Warfarin Pharmacogenomics in Underrepresented Populations.” College of Pharmacy Grand Rounds. University of Georgia, Athens, GA. February 26, 2013.

“The Promises and Challenges of Pharmacogenetics and Personalized Medicine.” Graduate seminar on pharmacogenomics and personalized medicine, University of Florida, Gainesville, FL. March 2, 2013.

“Pharmacogenetics: Clinical Applications & Implications for PharmD Programs.” Science Plenary, 2013 Annual Meeting of the American Association of Colleges of Pharmacy. Chicago, IL. July 15, 2013.

“Implementing Warfarin Pharmacogenetics.” Scientific Advisory Board meeting, Physicians Choice Laboratory Service. Rock Hill, SC. August 27, 2013.

“Cutting Edge Medicine: Pharmacogenetics on the Horizon.” 9<sup>th</sup> Annual New England Pharmacists Association Convention. Mashantucket, CT. September 20, 2013.

“Warfarin Pharmacogenetics – Evidence and Clinical Implementation.” Pharmacogenomics and Personalized Medicine: Progress in Clinical Implementation Symposium. 10<sup>th</sup> International Meeting of the Society for the Study of Xenobiotics. Toronto, Ontario, Canada. September 30, 2013.

“Implementation of a Warfarin Genetics Service at an Academic Medical Center.” Fall Meeting of the Kentucky Society of Health-System Pharmacists. French Lick, IN. October 10, 2013.

"Clinical Pharmacogenetics - Focus on Cardiovascular Pharmacotherapy"  
PK/PD/Pharmacogenetics PRN Symposium entitled "Applying Pharmacogenetics to Patient Care." 2013 American College of Clinical Pharmacy Annual Meeting, Albuquerque, New Mexico, October 14, 2013.

"African American Dosing Algorithms" as part of the "IWPC Update: Advancing Warfarin Pharmacogenomics," Pharmacogenomics Research Network – Research in Progress Seminar series. November 8, 2013.

"Genomics in Heart Failure: Additive or Redundant." SMP.301. Personalized Medicine: Pharmacogenomics & Metabolomics- Is That Your Final Answer? American Heart Association Scientific Sessions. Dallas, TX. November 17, 2013.

"Warfarin and the Translation of Basic Knowledge into Clinical Practice: What Have We Learned?" 2<sup>nd</sup> Annual Jacques de Champlain Scientific Symposium, "The risk of personalized cardiovascular medicine: treating N of 1?" Montreal Heart Institute. Montreal, Canada. December 2, 2013.

"Applying Personalized Medicine in Cardiovascular Care." American Pharmaceutical Association Annual Meeting. Orlando, FL. March 31, 2014.

"Outcomes with a Warfarin Pharmacogenetics Consult Service." Hot Topic at the Pharmacogenomics Research Network (PGRN) Scientific Meeting. Orlando, FL. April 2, 2014.

"Personalized Warfarin Dosing: Implications of Recent Data for Clinical Practice." Purdue University Department of Pharmacy Practice Seminar. Indianapolis, IN. April 16, 2014.

"UF Health Personalized Medicine Program (PMP): Current and Future Pharmacogenetic Implementations." University of Florida Medicine Grand Rounds. Gainesville, FL. May 8 2014.

"Pharmacogenetic Implementation – Opportunities and Challenges." For session entitled, "Advanced Applications of Molecular Diagnostics and Pharmacogenomics in Targeted Therapeutics." American Association for Clinical Chemistry Annual Meeting and Clinical Laboratory Exposition. Chicago, IL. July 27, 2014.

"Warfarin Pharmacogenetics – Predicting Response in Minority Populations." Phenotype Prediction Using Genomic Data Workshop. Cancer & Genetics Research Complex, Gainesville, FL. August 11, 2014.

"UF Health Personalized Medicine Program (PMP): An Update of *CYP2C19* Testing for Clopidogrel," University of Florida Cardiology Grand Rounds. Gainesville, FL. September 4, 2014.

"Personalized Medicine: Applications in Family Medicine." Family Medicine Conference – PCP Live Session #8. Gainesville, FL. September 17, 2014.

"Cardiovascular Pharmacogenomics: Applications to Patient Care." Balassone Lecture at the University of Maryland School of Pharmacy. October 6, 2014.

“Clinical Research: Getting off on the Right Foot and Sustaining the Momentum.” Professional Development Roundtable: Topics for Postgraduate Trainees. American College of Clinical Pharmacy annual meeting. Austin, TX. October 12, 2014.

“Pharmacogenetics versus Traditional Strategies for Warfarin Dosing.” Session Title: Challenges and Opportunities in Personalized Medicine. American Heart Association Scientific Sessions. Chicago, IL. November 18, 2014.

“Implementation of a Pharmacogenomics Service into Clinical Practice.” How to Set Up a Clinical Pharmacogenomics Service: Advice from Established Services. American Society of Health-System Pharmacists 2014 Midyear Clinical Meeting and Exhibition. ACPE Activity #0204-000-14-319-L04-P. Anaheim, CA. December 7, 2014.

“Pharmacogenomic Applications to Patient Care.” CME program for St. Anthony’s Hospital Baycare Health System, St. Petersburg, FL. February 10, 2015.

“Personalized Medicine: Applications in Pediatric Medicine.” University of Florida Pediatric Grand Rounds. Gainesville, FL. March 19, 2015.

“Clinical Implementation of Pharmacogenomics.” Presentation to the Novation Clinical Pharmacy Advisor Group, Dallas, TX. March 26, 2015.

“Precision Medicine – Supporting Evidence and Clinical Application.” Presentation at the 2015 Annual Meeting of the Western Medicaid Pharmacy Administrators Association. Whitefish, MT. September 30, 2015.

“UF Health Personalized Medicine Program (PMP): An Update of *CYP2C19* Testing for Clopidogrel,” CME program for the University of Florida Angiography and Interventional Fellows Conference. Gainesville, FL. October 5, 2015.

“Fellowships – Overall Goals and Finding Programs.” Professional Development Roundtable: Topics for Postgraduate Trainees. American College of Clinical Pharmacy Annual Meeting. San Francisco, CA. October 18, 2015.

“Basic Pharmacogenomics for the Heart Failure Clinician.” 2015 Comprehensive Heart Failure Review. Heart Failure Society of America. Tampa, FL. October 23, 2015.

“Pharmacogenomics – From Evidence to Implementation.” Distinguished Lecturer, Endowed Chu Lectureship. Idaho State University College of Pharmacy. Meridian, ID. November 5, 2015.

“Pharmacogenetics.” Oak Hammock Institute for Learning in Retirement. Gainesville, FL. November 6, 2015.

“The University of Florida Pharmacogenomics Program and its Priorities.” AssureRx Health Leadership Team and Scientific Advisory Board. Orlando, FL. January 19, 2016.

“Cardiovascular Pharmacogenetics: Clinical Implementation and Outcomes.” Center for Pharmacogenomics and Individualized Therapy. University of North Carolina, Chapel Hill, NC. February 9, 2016.

“Cardiology Pharmacogenomics I: Clopidogrel – *CYP2C19* and Simvastatin – *SLCO1B1*”  
University of Florida Precision Medicine Conference. Lake Nona, FL. March 10, 2016.

“Cardiology Pharmacogenomics II: Warfarin – *CYP2C9*, *VKORC1*, *CYP4F2*.” University of  
Florida Precision Medicine Conference. Lake Nona, FL. March 10, 2016.

“Cardiology Cases I: Clopidogrel – *CYP2C19* and Simvastatin – *SLCO1B1*” University of  
Florida Precision Medicine Conference. Lake Nona, FL. March 10, 2016.

“Cardiology Cases II: Warfarin – *CYP2C9*, *VKORC1*, *CYP4F2*.” University of Florida Precision  
Medicine Conference. Lake Nona, FL. March 10, 2016.

“Pharmacogenomics in the Hospital Pharmacy Setting.” Continuing Education Program  
delivered via teleconference for MedAssets Performance Management Solutions, Inc. March 17,  
2016.

“*CYP2C19* Genotype Testing and Clopidogrel Dosing – Real World Experience and Case  
Examples.” Precision Medicine Intensive, American College of Cardiology 65<sup>th</sup> Annual Scientific  
Session & Expo. Chicago, IL. April 4, 2016.

“Precision Medicine: What is it & how can it improve healthcare?” University of Florida Eye  
Opener Discovery Breakfast. Gainesville, FL. April 13, 2016.

“Warfarin Pharmacogenetics.” Lecture for the American Society of Health-System Pharmacist  
Pharmacogenomics Educational Series. Recorded August 8, 2016.

“Clopidogrel and Simvastatin Pharmacogenetics.” Lecture for the American Society of Health-  
System Pharmacist Pharmacogenomics Educational Series. Recorded August 8, 2016.

“Screening for *CYP2C19* Variants in Patients Undergoing Cardiac Catheterization.” IGNITE  
(Implementing Genomics in Practice) Unifying the Evaluation and Implementation of Genomic  
Medicine. Bethesda, MD. August 18, 2016.

“UF Health Personalized Medicine Program (PMP): An Update of *CYP2C19* Testing for  
Clopidogrel,” CME program for the University of Florida Angiography and Interventional Fellows  
Conference. Gainesville, FL. October 3, 2016.

“Pharmacogenomics and Predictive-Prescribing: Are We There Yet?” 2016 American College of  
Clinical Pharmacy Annual Meeting. Hollywood, FL. October 23-26, 2016.

“Precision Medicine: What is it and how can it improve healthcare?” Seminar for the Animal  
Molecular and Cellular Biology Graduate Program. University of Florida. November 4, 2016.

“Pharmacogenetics and Predictive Prescribing.” University of Wisconsin College of Pharmacy.  
December 14, 2016.

“Precision Medicine – Using Genotype to Inform Prescribing.” Canon Biosciences, Rockville,  
MD. February 21, 2017.

“Clinical Applications in Cardiovascular Pharmacogenetics.” University of Florida Precision  
Medicine Conference. Orlando, FL. March 8, 2017.



“Inpatient Implementation Perspectives and Discussion.” University of Florida Precision Medicine Conference. Orlando, FL. March 8, 2017.

“Outcomes with *CYP2C19* Genotyping for Clopidogrel Response: An Update from the IGNITE Network.” Clinical Pharmacogenetics Implementation Consortium (CPIC) 2017 Conference Using Pharmacogenetic Tests in Patient Care. Washington, DC. March 15, 2017.

“Evaluating Outcomes with Genotype-Guided Antiplatelet Therapy.” Genomic Medicine 10 Meeting. Silver Spring, MD. May 3, 2017.

“Update on Warfarin Pharmacogenetics – New CPIC Guidelines and Results from GIFT.” Lecture for the American Society of Health-System Pharmacist Pharmacogenomics Educational Series. Recorded June 16, 2017.

“*CYP2C19* Genotype-Guided Antiplatelet Therapy after Percutaneous Coronary Intervention.” Videoconference to Econogenomics Group from Brigham and Women’s Hospital and Harvard Medical School. June 20, 2017.

“Pharmacogenetics: The Impact of Genotype for Tailoring Drug Therapy.” NIH National Institute of Nursing Research. “Precision Health: From ‘Omics’ to Data Science” Boot Camp. Bethesda MD. August 7, 2017.

“Precision Medicine: The Past is FINALLY the Present.” 21<sup>st</sup> Annual Scientific Meeting of the Heart Failure Society of America. Dallas, TX. September 17-19, 2017.

“Optimizing Drug Therapy through Pharmacogenomics.” J.K. Lawton Lecture. Annual Pharmacy Association of Nova Scotia Pharmacy Conference. Digby, Nova Scotia. October 13, 2017.

“UF Health Personalized Medicine Program: Clinical Implementation of Genotype-Guided Therapies.” 2017 Southeastern Association of Pathology Chairs (SEAPC) and Pathology Department Administrators (PDAS) Annual Conference. St. Augustine, FL. October 27, 2017.

“Implementing and Assessing Outcomes with Genotype-Guided Therapy.” Association for Molecular Pathology 2017 Annual Meeting. Salt Lake City, Utah. November 16-18, 2017.

“Precision Medicine: Using Genotype to Inform Prescribing.” Webinar for LabRoots Drug Discovery 2018 virtual event. February 9, 2018.

“Genetic Testing to Predict Medication Effects and Chronic Disease Risk in Cardiology: Is It Ready for Prime Time? - Genotype-Guided Warfarin Dosing.” University of Florida Precision Medicine Conference. Orlando, FL. March 9, 2018.

“Pharmacogenetic Testing for Pain Management: A Prescription for Relief - Implementation and Impact of *CYP2D6*-Guided Pain Management on Patient Reported Outcomes.” University of Florida Precision Medicine Conference. Orlando, FL. March 9, 2018.

Panelist. “Controversial Topics in Pharmacotherapy.” American College of Cardiology 67<sup>th</sup> Annual Scientific Session. Orlando, FL. March 10, 2018.

“Genotype-Guided Antiplatelet Therapy after PCI.” Cardiology Grand Rounds. University of Rochester. Rochester, NY. May 10, 2018.

“Pharmacogenetic Opportunities in Depression and Pain Management.” 2018 Missouri Pharmacy Association Annual Meeting. Branson, MO. September 7, 2018.

“Clinical Implementation of Pharmacogenomics and Building Evidence to Support Implementation.” Mayo Clinic Individualizing Medicine Conference 2018, Rochester, MN. September 12-13, 2018.

“Real-world Application of Precision Pharmacotherapy.” 2018 American College of Clinical Pharmacy Global Conference. Seattle, WA. October 20-23, 2018.

“Challenges and Solutions for Precision Medicine in Diverse Patient Populations - Genotyping for Variants Important Across Ancestry Groups.” University of Florida Precision Medicine Conference. Orlando, FL. March 7, 2019.

“Implementation Barriers in Precision Medicine.” University of Florida Precision Medicine Conference. Orlando, FL. March 8, 2019.

“Pharmacogenetics in Cardiology: Where are We Now?” MedStar Genetic Medicine: Pharmacogenomics 2019 Conference. Bethesda, MD. March 23, 2019.

“Pharmacogenetics: From Discovery to Implementation in Practice”. Keynote speaker for the 29<sup>th</sup> University of North Texas Health Science Center Research Appreciation Day. Fort Worth, TX. March 29, 2019.

“Implementation and Outcomes in CYP2D6 Guided Pain Management”. Clinical Pharmacogenetics Implementation Consortium (CPIC) Open Meeting, St. Jude Children’s Research Hospital, Memphis, TN. June 6-7, 2019.

“Outcomes with Pharmacogenetic Implementation in Clinical Practice.” Global Gator Meeting, Reims, France. June 29, 2019.

“Overview of Genetics.” Florida Medical Association Annual Meeting. Orlando, FL. August 10, 2019.

“Pharmacogenomics.” Florida Medical Association Annual Meeting. Orlando, FL. August 10, 2019.

“UF Health Precision Medicine Program.” American Society of Health-System Pharmacists Foundation webinar. Presented as collaborative effort of with multiple team members. November 11, 2019. \*Prepared slides and script but unable to present due to Family Medical Leave.

“The UF Precision Medicine Program: Clinical Implementation of Pharmacogenomics.” 2019 Fall Mini Medical School. November 15, 2019.

“Building you Network.” Invest in Yourself: A Professional Development Series. Annual Workshop hosted by Student Affairs, APhA-ASP and PLS for students to learn skills that are

important to prepare for the next steps in their careers. College of Pharmacy, University of Florida, Gainesville, FL. December 2, 2019.

“Implementation of Pharmacogenomics in Clinical Care: Tools, Resources, and Outcomes.” Scientific Symposium: Pharmacogenomics in Epilepsy: Existing and Emerging Opportunities for Intervention. 73<sup>rd</sup> American Epilepsy Society Annual Meeting. Baltimore, MD. December 10, 2019.

“Pharmacogenetics in Practice: Implementation and Outcomes.” Keynote speaker at the Precision Medicine and Pharmacogenomics: Propelling Practice and Proof in Populations Symposium. University of Arizona, College of Medicine. Phoenix, AZ. January 17, 2020.

“Evidence-Based Pharmacogenomics: A Crucial Piece of the Implementation Puzzle.” University of Florida Precision Medicine Conference. Lake Nona, FL. February 2020. \*Prepared slides and script for presentation but unable to present due to Family Medical Leave.

“Moving Pharmacogenomics into Practice: It’s All About the Evidence.” Co-chair for novel format session accepted for presentation at the 2020 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics set to take place in March 2020, but cancelled secondary to COVID-19 pandemic.

“Future of Pharmacogenomics.” Invited keynote speaker for the University of Minnesota College of Pharmacy Pharmacogenomics Conference entitled “Implementation of Pharmacogenomics into Clinical Care” set to take place in June 2020, but cancelled secondary to COVID-19 pandemic.

## **AWARDS AND HONORS**

CRC Press Freshman Chemistry Award, Georgia Southern University, 1987

Kenneth L. Waters Pharmacy Scholarship, University of Georgia, 1989-1990

Rho Chi Certificate of Excellence, University of Georgia, 1991

Merck Award of Academic Excellence, University of Georgia, 1991

Fellow, American Foundation for Pharmaceutical Education for the Biomedical Research Sciences, 1999-2000.

Kenneth F. Finger Memorial Award for Excellence in Clinical Pharmacy Research, University of Florida, 2000

Winner, American College of Clinical Pharmacy 2000 Annual Meeting Best Student, Resident, Fellow Paper Award Competition

American Association of Colleges of Pharmacy-American Foundation for Pharmaceutical Education Pharmacy Faculty New Investigator, 2004

Teacher of the Year Honorable Mention Award from the Pharmacy Class of 2007, University of Illinois at Chicago, Academic year 2004-2005.

Teacher of the Year Nominee from the Pharmacy Class of 2008, University of Illinois at Chicago, Academic year 2005-2006.

Teacher of the Year Nominee from the Pharmacy Class of 2009, University of Illinois at Chicago, Academic year 2006-2007.

Hans Vahlteich Research Award, College of Pharmacy, University of Illinois at Chicago, 2007

Fellow, American College of Clinical Pharmacy, elected 2008

Best Paper, 2009 American College of Clinical Pharmacy and International Congress on Clinical Pharmacy

Kenneth F. Finger Fellow Alumni Lecturer Award, University of Florida, 2009

Member of the Month, April 2010, American Society of Clinical Pharmacology and Therapeutics  
Elected Trustee, Research Institute, American College of Clinical Pharmacy, 2013 to 2016  
Chair, Research Institute, American College of Clinical Pharmacy, 2014 to 2016  
Master Mentor, UF Clinical and Translational Science Institute, 2016  
Best Clinical Research Paper, University of Florida College of Pharmacy, 2017  
Outstanding Paper Award, American College of Clinical Pharmacy Cardiology Practice and Research Network, 2018  
Finalist, American Society of Health-System Pharmacist Award for Excellence in Medication Safety, 2018  
University of Florida Term Professor, 2018-2021  
Pharmacogenomics Research Network Featured Investigator, January 2019

## **PROFESSIONAL SERVICE**

### American College of Clinical Pharmacy

- Course Instructor, Updates in Therapeutics: Pharmacotherapy Preparatory Course. “Outpatient Cardiology” and “Critical Care.” 2001 to 2003.
- Reviewer, Pharmacotherapy Self Assessment Program, 5<sup>th</sup> edition
- Reviewer, Pharmacogenomics: Applications to Patient Care, 2<sup>nd</sup> edition
- Reviewer, Cardiology PRN Grant Award, 2011-2013
- Reviewer, Clinical Reasoning Series Professional Review – Pharmacogenomics
- ACCP Representative, Pharmacist Education in the Era of Genomic Medicine, a collaboration of multiple pharmacy organizations to develop competencies for pharmacists in genomics and pharmacogenomics, 2014
- Elected Member, Research Institute, 2013-2016
- Elected Chair, Research Institute, 2014-2016
- Mentor, MERIT Program, 2015-2017
- Reviewer, Updates in Therapeutics: Cardiology Pharmacy Preparatory Review Course. Pharmacogenomics of Cardiovascular Pharmacotherapies. August 2017.
- Peer Reviewer, Pharmacotherapy Self-Assessment Program 2019 Book 1 (Cardiology)
- Peer Reviewer, Cardiology Care Self-Assessment Program 2019 Book 2 (Special Populations)
- Committee and Task Force Service
  - 2002 to 2003: Member, Membership Committee
  - 2003 to 2004: Subcommittee Chair, Program Committee
  - 2004 to 2005: Member, Membership Committee
  - 2005 to 2006: Member, Research Committee
  - 2008 to 2009: Chair, Educational Affairs Committee
  - 2009 to 2010: Member, Student CV Review Service
  - 2009 to 2010: Member, FCCP Committee
  - 2010 to 2011: Chair, Educational Affairs Committee
  - 2011 to 2012: Member, Fellowship Credentialing Committee
  - 2012 to 2014: Vice Chair, Fellowship Credentialing Committee
  - 2014 to 2015: Secretary and Board Liaison, Research Affairs Committee
  - 2018: Precision Medicine Task Force

### American Society of Clinical Pharmacology and Therapeutics

- Committee Service

- 2007-2010, Education Committee member
- Abstract reviewer for 2010, 2017, 2018, 2019 annual meetings
- Late Breaking and Encore Abstract Reviewer for 2018, 2019 meetings
- Mentor, ASCPT Mentoring Program, 2014-2016
- Mentoring Task Force, 2015-2016
- Member, Scientific Program Committee, 2016-2019
- Mentor, Speed Mentoring Event, 2017, 2018, 2019 annual meetings
- Chair, Pharmacogenetics Poster Walk, 2018, 2019 annual meetings
- Member, Awards Nomination Task Force, 2019-2020

#### Association for Molecular Pathology

- Standardization of Clinically Relevant Pharmacogenetic Alleles (CYP2C9) Working Group, 2018
- Standardization of Clinically Relevant Pharmacogenetic Alleles (Warfarin) Working Group, 2019
- Standardization of Clinically Relevant Pharmacogenetic Alleles (CYP2D6) Working Group, 2020

#### Clinical Pharmacogenetics Implementation Consortium (CPIC)

- Writing Committee, Update to Warfarin Guideline
- Participant in 5 Phases of Delphi Process, Term Standardization for Clinical Pharmacogenetic Test Results
- Writing Committee, Proton Pump Inhibitor Guideline
- Writing Committee, Opioid Guidelines
- Steering Committee, May 2019 to present

#### Pharmacogenomics Research Network (PGRN)

- Affiliate member, 2010-2015
- Member, 2016 to present

#### Pharmacogenetics Variation (PharmVar) Consortium

- Member, CYP2C Expert Panel, 2018 to present

Manuscript Reviewer: *American Heart Journal (9/17), American Journal of Cardiology, American Journal of Health-System Pharmacy, American Journal of Medical Genetics, Annals of Internal Medicine (7/19), Annals of Pharmacotherapy, British Journal of Clinical Pharmacology (2/18), Cardiovascular Therapeutics (12/15), Case Reports in Medicine (1/16), Circulation, Circulation-Cardiovascular Genetics (12/15, 6/17), Circulation-Heart Failure (12/17), Circulation Journal (4/20), Cleveland Clinic Journal of Medicine, Clinical Chemistry (10/16), Clinical Chemistry and Laboratory Medicine, Clinical Medicine & Research, Clinical Pharmacokinetics, Clinical Pharmacology and Therapeutics (11/16, 3/17, 11/17, 1/18, 4/18, 3/19, 4/19), Clinical Research and Regulatory Affairs, Clinical and Translational Science (5/17, 10/17), Current Drug Safety (3/17), Current Medical Research and Opinion, Drug Metabolism and Personalized Therapy (11/17), Expert Opinion on Drug Metabolism and Toxicology (9/17), Expert Opinion on Pharmacotherapy, Expert Review of Precision Medicine and Drug Development (1/16), Frontiers in Genetics (2/19), Frontiers in Pharmacology (4/18), Future Cardiology, Genetics in Medicine (12/19), Genome Medicine (8/17), International Journal of Cardiology (11/19), JACC-Cardiovascular Intervention (11/17), JACC-Heart Failure (2/18), JAMA, Journal of the American Pharmacists Association, Journal of Endovascular Therapy, Journal of Cardiovascular Pharmacology (11/15, 1/17), Journal of Clinical Medicine (3/20),*

*Journal of Clinical Pharmacology* (5/16, 8/16), *Journal of Community Genetics, Molecular Diagnosis & Therapy*, *Journal of Thrombosis and Haemostasis* (3/17), *Pharmacist Letter* (1/17, 3/20), *Pharmacogenetics and Genomics* (10/17), *Pharmacogenomics* (5/15, 4/17, 6/17, 4/18, 8/18, 9/18), *The Pharmacogenomics Journal* (11/15, 1/16, 8/17, 12/17, 3/18, 5/18, 8/18), *Pharmacotherapy* (12/15, 6/16, 12/16, 11/17, 5/19, 10/19, 2/20), *PLOS One* (11/17, 3/18), *Puerto Rico Health Sciences Journal*, *Southern Medical Journal*, *Thrombosis, Thrombosis and Haemostasis* (11/15, 12/15)

#### Other Manuscript Reviews

- Expert Reviewer for NIH/NLM/NCBI manuscripts related to pharmacogenomics

#### Grant Review

10/2009 NIH CICS Study Section, ad hoc reviewer  
02/2010 NIH CICS Study Section, ad hoc reviewer  
02/2010 NIH Special Emphasis Panel on Microvascular Interactions, HP Study Section, ad hoc reviewer  
10/2010 NIH SAT/BTSS Member Conflict Study Section, ad hoc reviewer  
10/2010 Heart Research UK (HRUK), Translational Research Project Grants, ad hoc reviewer  
06/2011 NIH CICS Study Section, ad hoc reviewer  
12/2011 NIH ZRG1 CVRS-C(50), PAR10-238 ACCORD Ancillary Studies, Special Emphasis Panel, ad hoc reviewer  
03/2012 American Heart Association Thrombosis 2 Study Section, Peer reviewer  
10/2012 American Heart Association Vascular Wall, Lung and Thrombosis Clinical Committee, Peer reviewer  
03/2013 American Heart Association, Vascular Wall Biology Committee, Peer reviewer  
10/2013 American Heart Association, Vascular Wall Biology Clinical Committee, Peer reviewer  
10/2014 American Heart Association, Lipids, Lung, Thrombosis, Vascular Endo, Vascular Wall Bio Clinical Committee, Peer reviewer  
04/2015 American Heart Association, Vascular Wall Biology Clinical Committee, Peer reviewer  
08/2015 NIH ZGM1 PPBC-9 PG Scientific Review Group, ad hoc reviewer  
04/2016 American Heart Association, Lipids, Lung, Thrombosis, Vascular Wall Bio Clinical Committee, Peer reviewer  
06/2016 NIH Nursing and Related Clinical Sciences (NRCS) Study Section, ad hoc reviewer  
10/2016 NIH Nursing and Related Clinical Sciences (NRCS) Study Section, ad hoc reviewer  
03/2017 NIH ZRG1 HDM-Z (50) R, Special Emphasis Panel/Scientific Review Group, ad hoc reviewer  
06/2017 NIH ZGM1 PPBC-7 (PM), Special Emphasis Panel/Scientific Review Group, ad hoc reviewer  
02/2018 NIH Nursing and Related Clinical Sciences (NRCS) Study Section, ad hoc reviewer

#### Associate Editor

- *PharmaNote Pharmacogenetics Corner*, Quarterly publication in the PharmaNote newsletter to provide information about pharmacogenetic testing for clinicians in community practice nationwide. Established 2015.

#### Editorial Board Member

- *Future Cardiology*, Future Medicine Ltd, London
- *Pharmacogenomics Handbook*, Lexi-Comp, Incorporated, Hudson, OH
- *Pharmacotherapy*, 2015 to present
- *Frontiers in Pharmacogenetics and Pharmacogenomics*, 2016 to present
- *Therapeutic Advances in Cardiovascular Disease*, 2018 to present

#### Consultant and Advisory Board Activities

- Consultant, Lexi-Comp Inc., Hudson, OH

#### American Society of Health-System Pharmacists Antithrombosis Pharmacotherapy Traineeship

- Co-Preceptor, 2008, 2009

### **COLLEGE AND UNIVERSITY SERVICE**

#### Department of Pharmacy Practice, University of Illinois at Chicago

- Committee Service
  - Task Force on Laboratory Space, 2001-2002
  - IRB Review and Surveillance, 2001-2008
  - Residency Research Committee, 2003-2011
  - Research Strategic Planning Committee, 2009-2010
  - Faculty Search Committee, 2009-2011
  - Faculty Advisory Committee, elected 2009-2011; re-elected 2011-2013
  - Clinical Track Promotion Review Committee (Chair), 2010
  - Promotion and Tenure Committee, 2010-present
  - Clinical Tenure Track Ad-hoc Committee, 2011
- Mentoring Program (established 2012), Mentor to one faculty member
- Pharmacy Practice Residency Research Advisor, 2001-2011

#### College of Pharmacy, University of Illinois at Chicago

- Committee Service
  - Student Faculty Relations Committee, 2002-2004
  - Committee on Committees, 2004-2006
  - Scholarship and Awards Committee, 2006-2008
  - Grant Review Committee, 2008/2009 Hans Vahlteich Research Award
  - Student Disciplinary Committee, 2008-present
  - Curriculum Revision Task Force, Subcommittee on Joint Degree Programs, 2012
  - Grant Review Committee, 2012/2013 Hans Vahlteich Research Award
  - Member, Thesis Defense Committee, Department of Biopharmaceutical Sciences, July 2012 (Candidate, David Vaynshteyn)
- Judge, UIC College of Pharmacy Research Day, 2010, 2011, 2012, 2014
- Academic Advisor (up to 5 students per year)

#### University of Illinois at Chicago

- Faculty Senate, College of Pharmacy At Large Representative, 2003 to present
  - Member, Senate Research Committee, 2003 to 2007
  - Member, Academic Services Committee, 2007 to 2008

- Member, Center for Clinical and Translational Science Research Education and Careers in Health (REACH) Program Curriculum Committee, 2009 to 2012
- Member, Thesis Defense Committee, Department of Chemistry, June 2010 (Candidate, Christopher B. Dezutter)
- Member, Institute of Human Genetics Strategic Planning Committee, 2011 to 2014
- Member, Biobank Review Committee, Biomarkers of Health and Disease, 2012 to 2014

#### College of Pharmacy, University of Florida

- Judge, Graduate Student Posters, College of Pharmacy 28<sup>th</sup> Annual Research Showcase
- Member, Research Strategic Planning Committee, Fall 2015
- Mentor, Florida Society of Health System Pharmacy Student Organization Mentor Night, Spring 2016
- Member, Graduate Education Task Force, 2016-present
- Co-Coordinator, 2016 Pharmacogenomics Research Internship for Florida A&M University Pharmacy Students
- Co-Coordinator, 2015-2018 Department of Pharmacotherapy and Translational Research Seminar Series
- Participant, Pharmacy Campaign Strategy 2015-2016
- Research Committee, 2016-
- Tenure and Promotion Committee, 2016-2020
- PROSPER Grant Review Committee, 11/2016, 11/2017
- Exemplary Clinician Award Committee, 4/2017, 4/2018
- Provided 2-hour shadowing experience for Summer Health Professions Education Program (SHPEP), 6/2017, 6/2018
- UF Opportunity Fund Grant Review Committee, 11/2016, 12/2017
- Search Committee, Pharmaceutics Chair and Center for Pharmacometrics Director, Spring 2018

#### Health Center, University of Florida

- Member, Personalized Medicine Program Subcommittee
- Member, Cancer Center
- Member, Cancer Center Scientific Review and Monitoring Committee, January 1, 2017 to July 2017. Responsible for providing initial review for scientific merit, methodology, validity of statistical analysis, potential feasibility based upon anticipated accrual goals and scientific priority of clinical research studies in the Cancer Center
- Reviewer, CTSI Patient-Oriented Clinical Pilot Application, April 2017
- Moderator, CTSI Research Day Poster Session, June 2018
- Reviewer, CTSI Precision Health Initiative Pilot Grant Proposals, June 2019
- Reviewer, CPS/CTHR Collaborative Pilot Project Proposals, August 2019
- Reviewer, CTSI Pilot Grant Proposals, December 2019

#### University of Florida

- Member, Planning Committee, 2nd Annual Personalized Medicine Conference, Beyond the Promise: Addressing Evidence and Value in Personalized Medicine, October 2-3, 2015. Tampa, FL.
- Member, Genetics Institute Symposium Committee, 2016-2018



- Reviewer, UF CAMPAS Pilot Award, March 2020

## TEACHING

### Post-Doctoral Fellows

Kathryn Momary, PharmD, 07/2004 to 07/2007. Currently Associate Professor and Vice Chair, Department of Pharmacy Practice, Mercer University, Atlanta, GA  
Adam Bress, PharmD, MS-CTS, 07/2011 to 07/2013. Currently Assistant Professor, Department of Population Health Sciences, University of Utah, Salt Lake City, UT  
Katarzyna Drozda, PharmD, MS-CTS, 07/2012 to 06/2014. Currently Reviewer, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration  
Scott Mosley, PharmD, 07/2015 to 05/2018. Currently Assistant Professor of Clinical Pharmacy, University of Southern California, Los Angeles, CA  
Donald Max Smith, PharmD, 07/2017 to 06/2018. Currently Clinical Pharmacogenomics Specialist, MedStar Institute for Innovation  
Nihal El Rouby, PharmD, PhD, 07/2017 to 08/2019. Currently Assistant Professor of Pharmacy Practice & Administrative Sciences, University of Cincinnati  
Cameron Thomas, PharmD, 07/2018 to present

### Graduate Student Teaching

Kia Fuller, PhD candidate, University of Florida. Graduate committee member. 2014-2019. Examining the roles of genetics and sociocultural environment in health: Investigating complex disease through a biocultural lens  
Leanne Dumeny, MD/PhD student, University of Florida. Graduate committee co-chair.  
Salma Bargal, PhD candidate, University of Florida. Rotation Fall 2016.  
Loulia Akram Bader, MSc candidate, Qatar University, Dohar, Qatar, Spring 2017.  
Alaa Radwan, MSc candidate, Zagazig University, Egypt. Study of genetic polymorphisms and their association with lipid lowering effect of simvastatin and simvastatin-induced myopathy in Egyptian patients. Fall 2016 – Spring 2017  
Zainab Omer Ali, MSc candidate, Qatar University, Dohar, Qatar, Spring 2019.  
Islam El-Jilany, PhD candidate, Qatar University, Dohar, Qatar, Fall 2019-present.

### Visiting Scholar

Shaimaa F. Mohammed Kalil, MSc candidate, Misr International University. Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. May 18, 2015 – June 30, 2015  
Lukas Kovar, PharmD student, Germany. November 1, 2017 – April 12, 2018. Impact of different P2Y12 inhibitors on cardiovascular outcomes in diabetic patients: novel insights from real-world data.  
Neven Sarhan, MSc candidate, Misr International University. Effect of genetic polymorphism on the clinical response to mineralocorticoid receptor antagonist therapy in Egyptians with heart failure. July 15, 2018 – September 15, 2018

### Summer Research Internship, College of Pharmacy, University of Florida

Tommie Brent Lovato, Second year pharmacy student, University of Florida, Summer 2015  
Jennifer Kight, Second year pharmacy student, University of Florida, Summer 2015  
Sara Sterling, Third year pharmacy student, University of Florida, Summer 2016  
Cara Nys, Second year pharmacy student, University of Florida, Summer 2016  
Monique Westley, Second year pharmacy student, Florida A&M University, Summer 2016  
Judith Lovince, Second year pharmacy student, Florida A&M University, Summer 2017

Olayemi Oladapo, Second year pharmacy student, Florida A&M University, Summer 2018  
Reesie Owens, Second year pharmacy student, University of Florida, Summer 2018  
Natalie Ponce, Second year pharmacy student, University of Florida, Summer 2018  
Margarita Gonzalez, Second year pharmacy student, University of Florida, Summer 2019

#### Visiting Student

Kim Nguyen, Second year pharmacy student, Keck Graduate Institute, School of Pharmacy, June 2015  
Miguel Zayas, Third year pharmacy student, Mercer University College of Pharmacy, June 2016

#### Faculty Mentoring, University of Florida

Sihem Bihorel, PharmD, PhD, Assistant Professor of Pharmaceutics, 2015-present  
Meghan Arwood, PharmD, MS candidate, Clinical Assistant Professor of Pharmacotherapy and Translational Research, 2017-present  
Julio Duarte, PharmD, PhD, Assistant Professor of Pharmacotherapy and Translational Research, 2017-present  
Sophia S. Sheikh, MD, Assistant Professor of Emergency Medicine, 2017 to present.

#### *University of Illinois at Chicago*

##### PHAR 353 / 374, Medicine Clerkship (Required)

2001-2003: Lecturer / Facilitator. Case-based lecture on the treatment of heart failure for 3 contact hours. Enrollment – 20 to 30 P4 students per semester.

##### PHAR 402, Principles of Drug Action and Therapeutics II, 4 credit hour course (Required)

Fall Semester 2004-2005: Lecturer and Recitation Leader. *Introduction and Therapeutics of Heart Failure*, 2 lecture hours and 1 recitation case study (6 contact hours). Enrollment – approximately 160 P2 students.

Fall Semester 2001: *Pharmacogenomics*, 1 lecture hour. Enrollment – 155 second year Pharm.D. students.

##### PHAR 405, Principles of Drug Action and Therapeutics V (Required)

Fall Semester 2001: Lecturer and Recitation Leader in team-taught course. *Therapeutics of Hypertension*, 2 lecture hours and 2 recitation case studies (12 contact hours). Enrollment – approximately 150 P3 students.

##### PHYB 301, Human Physiology and Pathophysiology I, 5 credit hour course (Required)

Fall Semester 2001-2004: Lecturer in team-taught course. *Pathophysiology of Hypertension, Heart Failure, Coronary Artery Disease, Acute Coronary Syndromes, and Cardiac Arrhythmias*. 5 lecture hours. Enrollment – 150 to 160 P1 students.

##### PMPC 495, Biotech I (Graduate course)

Spring Semester 2002: Lecturer in team-taught course. Introduction to Pharmaceutical Research. *Pharmacogenetics*, 2 lecture hours. Enrollment – 4 College of Pharmacy Graduate Students.

##### PMPD 470, Clinical Pharmacology I (Elective)

Fall Semester 2001: Lecturer in team-taught course. *Cardiovascular Pharmacogenetics*, 1 lecture hour. Enrollment – 41 P1 students.

PMPR 326, Topics for Professional Enrichment (Elective)

Fall Semester 2002-2003: Lecturer in team-taught course. *Post graduate training*, 1 lecture hour. Enrollment – approximately 100 PharmD students.

PMPR 360, Clinical Aspects of Drug Interactions, Metabolism, and Pharmacogenetics (Elective)

Spring Semester 2002-2003: Lecturer in team-taught course. *Pharmacogenetics/ Pharmacogenomics II*, 2 lecture hours. Enrollment – approximately 20 PharmD Students.

PMPR 389, Critical Care Clerkship, 4 credit hours (Elective)

2002-2003: Preceptor. Cardiology Service, University of Illinois Hospital & Health Sciences System. Enrollment – 1 P4 student per 6 week rotation.

BPS 360, Survey of Basic and Clinical Pharmacology I, 1 credit hour course (Elective)

Fall Semester 2002-2004, 2007-present: Lecturer in team-taught course. *Autonomic Agents*, 2 hours. Enrollment – 100 to 120 P1 students.

BPS 555, Principles of Pharmacogenomics and Molecular Pharmacology (Required course for PhD students and elective for PharmD students)

Spring Semester 2004-Fall Semester 2009: Lecturer in team-taught course. *Pharmacogenomics: Drug Receptor and Ion Channel Genes*, 2004-2010, 2 hours. *Pharmacogenomics: Interaction of Genes Involved in Drug PK and PD*, 2010, 2 hours. Enrollment – up to 20 PhD and PharmD students.

PHAR 400, Pharmacokinetics, 3 credit hour course (Elective)

Spring Semester 2006-present: Lecturer in team-taught course. *Pharmacogenomics*, 1 hour. Enrollment – approximately 200 P1 students.

PHAR 402, Principles of Drug Action and Therapeutics II, 4 credit hour course (Required)

Fall Semester 2001-present: Lecturer and Recitation Leader in a team-taught course. *Therapeutics of Hypertension*, 2 lecture hours and 2 to 3 recitation case studies (14 to 20 total contact hours) per year. Enrollment – approximately 200 P2 students.

PMPR 355: Seminar in Pharmacy Research, 1 credit hour course (Elective)

Spring Semester 2004-present: Co-coordinator for a weekly seminar series. Enrollment – 40 P1 to P2 students on the Chicago and Rockford campuses.

PMPR 380/390, Undergraduate Research in Pharmacy Practice, 1 to 3 credit hours (Elective)

2001-present: Instructor for practical experience in clinical and basic science research. Enrollment – up to 5 P1 to P3 students per semester.

PMPR 388, Advanced Pharmacy Practice Specialty Experience, 4 credit hours (Elective)

2002-present: Preceptor for pharmacogenetics clerkship experience. Enrollment – 1 to 2 P4 students per 6 week rotation.

Introductory Pharmacy Practice Experience (IPPE)

2007-present: Preceptor for 1 week clerkship experience for 1 to 2 P1 students.

HON201, Introduction to Clinical and Translational Science.

2011-2012: Instructor in an Honors College course. *Application of Clinical Translational Research*, 1.5 hours. Enrollment – up to 20 undergraduate students.

HPA/PMPG, Concepts in Drug Development: From Bench to Bedside, 1 credit hour.

2011: Recorded lecture. *Pharmacogenetics: Genetic Contributions to Drug Response*, 1 hour. Enrollment – up to 25 healthcare professionals enrolled in the Research Certificate Program and P2 and P3 students.

HON201, A Decade of Pharmacy Experiences: From Pharmacy Student to Pharmacist in the Workforce (Elective)

2013-2014: Instructor in an Honors College course. *Clinical and Basic Research*, 1.0 hour. Enrollment – up to 30 undergraduate students enrolled in the Honors College.

#### *University of Florida*

PHA 5782: Pharmacotherapy II (Required)

1998-2000: Lecturer. Team-taught therapeutics course for the second year PharmD students with class sizes of 100-120 students. Delivered 2 to 3 lectures per year on cardiovascular pharmacotherapy (coronary artery disease and arrhythmia management) and facilitated approximately 20 recitation sessions per year.

PHA 5516: Practicum I (Required)

1998: Small Group Facilitator. Supervised first-year PharmD students as they practiced interview and physical assessment skills at a senior activity center.

CPET: UF Health Personalized Medicine Program 2014

Lecture for 2 high school teachers. *Pharmacogenetics Overview* (1.0 lecture hour); *Clinical and Practice Applications of Pharmacogenetics* (1.0 lecture hour)

PHA 5591: Circulatory Disorders.

Fall 2014: Instructor for Working Professional PharmD Program. *Cardiovascular Pharmacogenomics* (2 lecture hours).

PHA 5933/5012: Clinical Applications of Personalized Medicine (Elective)

Fall 2014 – Spring 2017: Lecturer for team-taught course for 2nd year PharmD students. *CYP2C19-Clopidogrel* and *SLCO1B1-Simvastatin* (2014, 2016); *Warfarin Pharmacogenomics* (2014-2016); *Cardiovascular Pharmacogenetics* (1.0 lecture hour, Spring 2017, Spring 2019).

PHA 5782: Pharmacotherapy II (Required)

Fall 2014 – Fall 2015: Lecturer for team-taught course for 2nd year PharmD students. Team-taught therapeutics course for the second year PharmD students. *Coronary Heart Disease* (2.0 lecture hours and 2.0 oral defense facilitations).

PHA 5113: Personalized Medicine

Fall 2014 – Fall 2016: Lecturer for team-taught course for 3<sup>rd</sup> year PharmD students. Team-taught course for PharmD students. *Pharmacogenomic Applications in Cardiovascular Disease I, Pharmacogenomics Applications in Cardiovascular Disease II, Personalized Medicine and the Pharmacist's Role* (3.0 lecture hours, Fall 2014-Fall 2016)

ANG 6532/ANT 4531: Molecular Genetics of Disease

Fall 2014, Fall 2017: Guest Speaker for course for anthropology and biology majors.  
*Pharmacogenomics* (1.0 lecture hour).

PHA 6633: MTM: A Cardiovascular Focus

Fall 2015, 2017, 2018: Lecturer for Medication Therapy Management Program.  
*Pharmacogenomics for Cardiovascular Drugs* (1.0 lecture hour; 2015, 2017), *Stable Angina Pectoris, Parts 1 and 2* (2.0 lecture hours, 2015), *Cardiovascular Pharmacogenetics* (1.0 lecture hour, 2017, repurposed lecture from PHA 5933).

PHA 6449: Section 13AG: Pharmacogenomics

Spring 2016, 2018: Lecturer for graduate level course. *Pharmacogenomics: Translation to Practice* (1.0 lecture hour).

PHA5878C: Patient Care 3 (Required)

Fall 2016: Module Leader for Ischemic Heart Disease (Module 3) and Heart Failure (Module 5). *Management of Ischemic Heart Disease* (1 lecture hour and 4 hours Team Based Learning session) *Management of Chronic Heart Failure* (2 lecture hours and 4 hours Team Based Learning session).

Fall 2017-2019: Module Leader for Heart Failure (Module 5). *Management of Chronic Heart Failure* (2.0 lecture hours and 4.0 hours Team Based Learning session).

Fall 2018, 2019: Lecturer. *Personalized Medicine – CV: Warfarin Pharmacogenetics*. (1.0 lecture hour)

PHA4933: Medications and Health

Fall 2016, Spring 2017: Lecturer for team taught course. *Pharmacogenomics: Anticoagulation* (1.0 lecture hour)

PHA 6935: Life Cycle of a Drug

Summer 2017, 2018, 2019: Assisted in course development and served as a lecturer for team taught course. *Pharmacogenomics: Clinical Implementation* (1 lecture hour)

PHA5788C: Patient Care 6 (Required)

Fall 2017, 2018, 2019: Lecturer. *Personalized Medicine in Pain Management*. (0.5 lecture hour).

PHA 5081C: Patient Care 8 (Required)

Spring 2018, Spring 2019: Lecturer. *Personalized Medicine – CV: Warfarin Pharmacogenetics*. (1.0 lecture hour)

HSC2000: Intro to Public Health and Health Professions

Spring 2019, Spring 2020: Lecturer. *A Career in Pharmacy – From Behind the Counter to in Front of the Classroom* (1 lecture hour).

PHA 6894: Introduction to Graduate Studies (Required)

Summer 2019: Lecturer. *Communication and Presentation Skills-III: Manuscripts* (1.5 lecture hour).

PHA5930: Seminar in Pharmacy Research (Elective, 2.0 credit hours)

Fall 2020: Course co-coordinator and presenter.

PHA5767: Precision Medicine APPE

Topic Discussion – Cardiovascular Pharmacogenetics (1.0 hour)

*International*

Recorded Lectures for pharmacists and physicians at the Khoo Teck Puat Hospital, Singapore

May 2013: *Introduction to Pharmacogenetics* (1 hour); *Variants in Drug Metabolism, Drug Transporter, and Drug Target Genes* (1 hour); *Pharmacogenetic Implementation in Clinical Practice* (1 hour); *Pharmacogenetic Research* (1 hour)

Live Video Conference for pharmacists and physicians at the Khoo Teck Puat Hospital, Singapore

May-June 2013: *Tutorial 1: Molecular Approaches to Pharmacogenetics* (1 hour); *Tutorial 2: Implementation of Pharmacogenetics* (1 hour)